Combinations    O
include    O
with    O
measles    B-Vaccine104517535
and    O
mumps    B-Vaccine104517535
vaccine    I-Vaccine104517535
(    O
MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
)    O
and    O
measles    O
,    O
mumps    O
and    O
varicella    B-Vaccine104517535
vaccine    I-Vaccine104517535
(    O
MMRV    B-Vaccine104517535
vaccine    I-Vaccine104517535
)    O
.    O

A    O
formulation    O
with    O
the    O
previous    O
three    O
and    O
the    O
varicella    B-Vaccine104517535
vaccine    I-Vaccine104517535
known    O
as    O
MMRV    B-Vaccine104517535
is    O
also    O
available    O
.    O

According    O
to    O
the    O
National    O
Cancer    O
Institute    O
,    O
a    O
tumor    B-Vaccine104517535
antigen    I-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
a    O
"    O
vaccine    O
made    O
of    O
cancer    O
cells    O
,    O
parts    O
of    O
cancer    O
cells    O
,    O
or    O
pure    O
tumor    O
antigens    O
(    O
substances    O
isolated    O
from    O
tumor    O
cells    O
)    O
"    O
.    O

Giant    O
Eagle    O
Pharmacy    O
also    O
offers    O
several    O
immunizations    O
across    O
the    O
year    O
for    O
Pneumonia    O
,    O
Influenza    O
,    O
and    O
Zostavax    B-Vaccine104517535
.    O

Zoster    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
a    O
live    B-Vaccine104517535
vaccine    I-Vaccine104517535
that    O
has    O
been    O
shown    O
to    O
reduce    O
the    O
incidence    O
of    O
herpes    O
zoster    O
(    O
known    O
as    O
shingles    O
)    O
The    O
zoster    O
vaccine    O
is    O
,    O
essentially    O
,    O
a    O
larger    O
-    O
than    O
-    O
normal    O
dose    O
of    O
the    O
chickenpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
as    O
both    O
shingles    O
and    O
chickenpox    O
are    O
caused    O
by    O
the    O
same    O
virus    O
,    O
the    O
varicella    O
zoster    O
virus    O
(    O
VZV    O
)    O
.    O

Plague    B-Vaccine104517535
vaccine    I-Vaccine104517535

In    O
the    O
early    O
21st    O
century    O
,    O
the    O
vaccine    O
market    O
greatly    O
improved    O
with    O
the    O
approval    O
of    O
the    O
vaccine    O
Prevnar    B-Vaccine104517535
,    O
along    O
with    O
a    O
small    O
number    O
of    O
other    O
high    O
-    O
priced    O
blockbuster    O
vaccines    O
,    O
such    O
as    O
Gardasil    B-Vaccine104517535
and    O
Pediarix    O
,    O
which    O
each    O
had    O
sales    O
revenues    O
of    O
over    O
$    O
1    O
billion    O
in    O
2008    O
.    O

Pneumococcal    B-Vaccine104517535
conjugate    I-Vaccine104517535
vaccine    I-Vaccine104517535

Heptavalent    O
conjugated    O
vaccine    O
for    O
children    O
(    O
PCV    B-Vaccine104517535
)    O

Pneumococcal    B-Vaccine104517535
conjugate    I-Vaccine104517535
vaccine    I-Vaccine104517535
(    O
PCV    O
)    O
in    O
early    O
infancy    O
,    O
decreases    O
the    O
risk    O
of    O
acute    O
otitis    O
media    O
in    O
healthy    O
infants    O
.    O

Pneumococcal    B-Vaccine104517535
polysaccharide    I-Vaccine104517535
vaccine    I-Vaccine104517535
(    O
not    O
before    O
2    O
years    O
of    O
age    O
)    O
.    O

23-serotype    O
vaccine    O
for    O
adults    O
(    O
PPV    B-Vaccine104517535
)    O

Meningococcal    B-Vaccine104517535
meningitis    I-Vaccine104517535
vaccine    I-Vaccine104517535

Beginning    O
with    O
the    O
2017    O
-    O
18    O
school    O
year    O
,    O
high    O
school    O
students    O
are    O
mandated    O
to    O
receive    O
a    O
dose    O
of    O
MCV    O
meningococcal    B-Vaccine104517535
conjugate    I-Vaccine104517535
vaccine    I-Vaccine104517535
for    O
12th    O
grade    O
entry    O
.    O

Beginning    O
with    O
the    O
2017    O
-    O
18    O
school    O
year    O
,    O
high    O
school    O
students    O
are    O
mandated    O
to    O
receive    O
a    O
dose    O
of    O
MCV    O
meningococcal    B-Vaccine104517535
conjugate    I-Vaccine104517535
vaccine    I-Vaccine104517535
for    O
12th    O
grade    O
entry    O
.    O

Beginning    O
with    O
the    O
2017    O
-    O
18    O
school    O
year    O
,    O
high    O
school    O
students    O
are    O
mandated    O
to    O
receive    O
a    O
dose    O
of    O
MCV    O
meningococcal    B-Vaccine104517535
conjugate    I-Vaccine104517535
vaccine    I-Vaccine104517535
for    O
12th    O
grade    O
entry    O
.    O

Beginning    O
with    O
the    O
2017    O
-    O
18    O
school    O
year    O
,    O
high    O
school    O
students    O
are    O
mandated    O
to    O
receive    O
a    O
dose    O
of    O
MCV    O
meningococcal    B-Vaccine104517535
conjugate    I-Vaccine104517535
vaccine    I-Vaccine104517535
for    O
12th    O
grade    O
entry    O
.    O

The    O
United    B-Vaccine104517535
States    I-Vaccine104517535
Military    I-Vaccine104517535
HIV    I-Vaccine104517535
Research    I-Vaccine104517535
Program    I-Vaccine104517535
(    O
USMHRP    B-Vaccine104517535
or    O
MHRP    B-Vaccine104517535
)    O
is    O
a    O
program    O
initiated    O
by    O
the    O
United    O
States    O
Congress    O
in    O
1986    O
.    O

CircoFLEX    B-Vaccine104517535
(    O
porcine    O
circovirus    O
vaccine    O
type    O
2    O
,    O
killed    O
"    O
Baculovirus    O
"    O
vector    O
)    O

Canine    O
influenza    O
is    O
caused    O
by    O
varieties    O
of    O
influenzavirus    O
A    O
,    O
such    O
as    O
equine    B-Vaccine104517535
influenza    I-Vaccine104517535
virus    O
H3N8    O
,    O
which    O
in    O
2004    O
was    O
discovered    O
to    O
cause    O
disease    O
in    O
dogs    O
.    O

Equine    B-Vaccine104517535
influenza    I-Vaccine104517535

The    O
Equine    B-Vaccine104517535
Influenza    I-Vaccine104517535
outbreak    O
in    O
2007    O
seriously    O
affected    O
the    O
early    O
part    O
of    O
Blacks    O
A    O
Fake    O
â€™s    O
seven    O
-    O
year    O
-    O
old    O
season    O
,    O
with    O
cancelled    O
races    O
,    O
travel    O
restrictions    O
and    O
the    O
fact    O
he    O
caught    O
the    O
disease    O
all    O
contributing    O
factors    O
.    O

Horses    O
with    O
horse    B-Vaccine104517535
flu    I-Vaccine104517535
can    O
run    O
a    O
fever    O
,    O
have    O
a    O
dry    O
hacking    O
cough    O
,    O
have    O
a    O
runny    O
nose    O
,    O
and    O
become    O
depressed    O
and    O
reluctant    O
to    O
eat    O
or    O
drink    O
for    O
several    O
days    O
but    O
usually    O
recover    O
in    O
two    O
to    O
three    O
weeks    O
.    O
"    O

Equine    B-Vaccine104517535
influenza    I-Vaccine104517535
,    O
the    O
disease    O
caused    O
by    O
strains    O
of    O
Influenza    O
A    O
that    O
are    O
enzootic    O
in    O
horse    O
species    O

However    O
,    O
the    O
trip    O
was    O
canceled    O
after    O
equine    B-Vaccine104517535
influenza    I-Vaccine104517535
was    O
reported    O
in    O
Australia    O
.    O

He    O
was    O
a    O
vocal    O
enthusiast    O
for    O
the    O
Smallpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
)    O
His    O
work    O
on    O
this    O
led    O
to    O
his    O
being    O
awarded    O
the    O
Order    O
of    O
the    O
Rising    O
Sun    O
,    O
4th    O
Class    O
in    O
1909    O
.    O

The    O
physician    O
Edward    O
Jenner    O
's    O
smallpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
said    O
to    O
have    O
"    O
saved    O
more    O
lives    O
...    O
than    O
were    O
lost    O
in    O
all    O
the    O
wars    O
of    O
mankind    O
since    O
the    O
beginning    O
of    O
recorded    O
history    O
.    O
"    O

By    O
1832    O
,    O
the    O
federal    O
government    O
of    O
the    O
United    O
States    O
established    O
a    O
smallpox    B-Vaccine104517535
vaccination    I-Vaccine104517535
program    O
for    O
Native    O
Americans    O
.    O

Under    O
the    O
direction    O
of    O
Mountstuart    O
Elphinstone    O
a    O
program    O
was    O
launched    O
to    O
increase    O
smallpox    B-Vaccine104517535
vaccination    I-Vaccine104517535
in    O
India    O
.    O

More    O
than    O
40,000    O
children    O
were    O
vaccinated    B-Vaccine104517535
against    O
smallpox    O
.    O

However    O
,    O
he    O
became    O
particularly    O
interested    O
in    O
Edward    O
Jenner    O
's    O
introduction    O
of    O
what    O
was    O
soon    O
to    O
be    O
known    O
as    O
smallpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
which    O
used    O
material    O
obtained    O
from    O
cases    O
of    O
cowpox    O
.    O

After    O
Edward    O
Jenner    O
introduced    O
the    O
smallpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
in    O
1798    O
,    O
variolation    O
declined    O
and    O
was    O
banned    O
in    O
some    O
countries    O
.    O

Smallpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
-    O
Edward    O
Jenner    O
with    O
his    O
discovery    O
is    O
said    O
to    O
have    O
"    O
saved    O
more    O
lives    O
(    O
...    O
)    O
than    O
were    O
lost    O
in    O
all    O
the    O
wars    O
of    O
mankind    O
since    O
the    O
beginning    O
of    O
recorded    O
history    O
.    O
"    O

Thomas    O
Nettleton    O
,    O
local    O
physician    O
who    O
carried    O
out    O
some    O
of    O
the    O
earliest    O
systematic    O
programs    O
of    O
smallpox    B-Vaccine104517535
vaccination    I-Vaccine104517535

Clemens    O
von    O
Pirquet    O
,    O
an    O
Austrian    O
physician    O
,    O
discovered    O
that    O
patients    O
who    O
had    O
previously    O
received    O
injections    O
of    O
horse    O
serum    O
or    O
smallpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
had    O
quicker    O
,    O
more    O
severe    O
reactions    O
to    O
a    O
second    O
injection    O
,    O
and    O
he    O
coined    O
the    O
word    O
"    O
allergy    O
"    O
to    O
describe    O
this    O
hypersensitivity    O
reaction    O
.    O

In    O
1798    O
he    O
gave    O
the    O
first    O
smallpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
at    O
Trinity    O
,    O
Newfoundland    O
.    O

He    O
suffered    O
from    O
poor    O
health    O
in    O
later    O
life    O
and    O
died    O
,    O
aged    O
58    O
,    O
at    O
Bedwell    O
from    O
an    O
adverse    O
reaction    O
to    O
a    O
smallpox    B-Vaccine104517535
vaccination    I-Vaccine104517535
.    O

research    O
on    O
smallpox    B-Vaccine104517535
vaccination    I-Vaccine104517535

Another    O
incident    O
recorded    O
was    O
the    O
Smallpox    O
plague    O
in    O
1879    O
,    O
a    O
disease    O
that    O
has    O
been    O
very    O
rare    O
on    O
these    O
coasts    O
since    O
the    O
discovery    O
of    O
the    O
smallpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Inoculation    O
was    O
thus    O
commonly    O
practised    O
by    O
surgeons    O
decades    O
before    O
1796    O
and    O
the    O
process    O
of    O
smallpox    B-Vaccine104517535
vaccination    I-Vaccine104517535
was    O
introduced    O
by    O
Edward    O
Jenner    O
.    O

The    O
agents    O
discover    O
a    O
large    O
complex    O
of    O
filing    O
cabinets    O
containing    O
smallpox    B-Vaccine104517535
vaccination    I-Vaccine104517535
records    O
and    O
tissue    O
samples    O
.    O

He    O
is    O
most    O
well    O
known    O
for    O
being    O
the    O
first    O
doctor    O
to    O
test    O
the    O
smallpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
in    O
the    O
United    O
States    O
,    O
which    O
he    O
carried    O
out    O
on    O
his    O
own    O
family    O
.    O

Other    O
drugs    O
introduced    O
during    O
this    O
time    O
include    O
Isordil    O
,    O
a    O
vasodilator    O
for    O
treatment    O
of    O
angina    O
,    O
Dryvax    B-Vaccine104517535
,    O
a    O
freeze    O
-    O
dried    O
smallpox    O
vaccine    O
,    O
and    O
Ovral    O
,    O
a    O
combined    O
oral    O
contraceptive    O
pill    O
.    O

Polyinosinic    O
:    O
polycytidylic    O
acid    O
(    O
usually    O
abbreviated    O
poly    O
I    O
:    O
C    O
)    O
is    O
an    O
immunostimulant    B-Vaccine104517535
.    O

Poly    O
ICLC    O
is    O
an    O
immunostimulant    B-Vaccine104517535
.    O

While    O
referred    O
to    O
as    O
a    O
therapeutic    O
vaccine    O
rather    O
than    O
a    O
preventive    O
vaccine    O
that    O
prevents    O
infectious    O
disease    O
,    O
sipuleucel    O
-    O
T    O
is    O
instead    O
an    O
immunostimulant    B-Vaccine104517535
.    O

For    O
example    O
,    O
female    O
sex    O
hormones    O
are    O
known    O
immunostimulator    B-Vaccine104517535
of    O
both    O
adaptive    O
and    O
innate    O
immune    O
responses    O
.    O

Immunostimulator    B-Vaccine104517535

Oncophage    B-Vaccine104517535
(    O
brand    O
name    O
Vitespen    B-Vaccine104517535
)    O
,    O
also    O
known    O
as    O
"    O
cancer    O
vaccine    O
heat    O
shock    O
protein    O
peptide    O
complex-96    O
"    O
and    O
"    O
cancer    O
vaccine    O
HSPPC-96    O
"    O
,    O
is    O
a    O
personalized    O
cancer    B-Vaccine104517535
vaccine    I-Vaccine104517535
developed    O
by    O
the    O
American    O
biopharmaceutical    O
company    O
Antigenics    O
Inc.    O

Clostridium    B-Vaccine104517535
vaccine    I-Vaccine104517535

The    O
best    O
prevention    O
against    O
viral    O
pneumonia    O
is    O
vaccination    O
against    O
influenza    B-Vaccine104517535
,    O
adenovirus    B-Vaccine104517535
,    O
chickenpox,    B-Vaccine104517535
herpes    I-Vaccine104517535
zoster    I-Vaccine104517535
,    O
measles    B-Vaccine104517535
,    O
and    O
rubella    B-Vaccine104517535
.    O

Rubella    B-Vaccine104517535
vaccine    I-Vaccine104517535

In    O
parallel    O
studies    O
,    O
Yirmiya    O
employed    O
unique    O
controlled    O
and    O
prospective    O
experimental    O
models    O
of    O
disease    O
in    O
humans    O
,    O
demonstrating    O
that    O
immune    O
challenges    O
,    O
such    O
as    O
endotoxin    O
administration    O
,    O
rubella    B-Vaccine104517535
vaccination    I-Vaccine104517535
or    O
minor    O
surgery    O
,    O
induce    O
cytokine    O
-    O
mediated    O
disturbances    O
in    O
behavioral    O
,    O
emotional    O
and    O
cognitive    O
functions    O
.    O

Cold    B-Vaccine104517535
chain    I-Vaccine104517535

Commercial    O
thermal    O
shopping    O
bags    O
,    O
to    O
carry    O
temperature    O
-    O
sensitive    O
purchases    O
home    O
without    O
breaking    O
the    O
cold    B-Vaccine104517535
chain    I-Vaccine104517535
,    O
were    O
first    O
introduced    O
by    O
grocery    O
and    O
other    O
shops    O
in    O
Europe    O
in    O
the    O
mid    O
1980s    O
.    O

The    O
labels    O
were    O
designed    O
in    O
response    O
to    O
the    O
problem    O
of    O
delivering    O
vaccines    O
to    O
developing    O
countries    O
where    O
the    O
cold    B-Vaccine104517535
chain    I-Vaccine104517535
is    O
difficult    O
to    O
preserve    O
,    O
and    O
where    O
formerly    O
vaccines    O
were    O
being    O
rendered    O
inactive    O
and    O
administered    O
ineffectively    O
due    O
to    O
their    O
having    O
been    O
denatured    O
by    O
exposure    O
to    O
ambient    O
temperature    O
.    O

Cold    B-Vaccine104517535
chain    I-Vaccine104517535
,    O
temperature    O
-    O
controlled    O
supply    O
chain    O

Cold    B-Vaccine104517535
chain    I-Vaccine104517535

enforcement    O
of    O
hygiene    O
procedures    O
such    O
as    O
HACCP    O
and    O
the    O
"    O
cold    B-Vaccine104517535
chain    I-Vaccine104517535
"    O
;    O

Due    O
to    O
the    O
aseptic    O
technology    O
,    O
there    O
was    O
no    O
longer    O
a    O
need    O
for    O
a    O
cold    B-Vaccine104517535
chain    I-Vaccine104517535
,    O
which    O
made    O
the    O
package    O
economical    O
and    O
suitable    O
for    O
warmer    O
climates    O
,    O
something    O
that    O
greatly    O
expanded    O
potential    O
markets    O
.    O

Measure    O
temperatures    O
(    O
humidity    O
,    O
etc    O
.    O
)    O
of    O
perishables    O
during    O
shipments    O
:    O
Cold    B-Vaccine104517535
chain    I-Vaccine104517535

Brucellosis    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
a    O
vaccine    O
for    O
cattle    O
,    O
sheep    O
and    O
goats    O
used    O
against    O
brucellosis    O
.    O

From    O
2006    O
-    O
2007    O
,    O
he    O
was    O
also    O
a    O
visiting    O
professor    O
at    O
the    O
Centre    O
for    O
Innovations    O
in    O
Medicine    O
,    O
Biodesign    O
Institute    O
,    O
Arizona    O
State    O
University    O
where    O
he    O
was    O
involved    O
in    O
the    O
area    O
of    O
genetic    B-Vaccine104517535
vaccines    I-Vaccine104517535
.    O

Of    O
those    O
,    O
the    O
most    O
promising    O
ones    O
are    O
DNA    B-Vaccine104517535
vaccines    I-Vaccine104517535
or    O
based    O
on    O
Venezuelan    O
equine    O
encephalitis    O
virus    O
replicons    O
,    O
vesicular    O
stomatitis    O
Indiana    O
virus    O
(    O
VSIV    O
)    O
or    O
filovirus    O
-    O
like    O
particles    O
(    O
VLPs    O
)    O
as    O
all    O
of    O
these    O
candidates    O
could    O
protect    O
nonhuman    O
primates    O
from    O
marburgvirus    O
-    O
induced    O
disease    O
.    O

American    O
medical    O
researchers    O
develop    O
a    O
painless    O
polymer    O
skin    O
patch    O
that    O
can    O
be    O
used    O
to    O
inject    O
DNA    B-Vaccine104517535
vaccines    I-Vaccine104517535
without    O
a    O
conventional    O
needle    O
,    O
and    O
also    O
increases    O
the    O
initial    O
effectiveness    O
of    O
the    O
vaccine    O
delivered    O
.    O

An    O
Immunization    B-Vaccine104517535
registry    I-Vaccine104517535
or    O
Immunization    B-Vaccine104517535
Information    I-Vaccine104517535
System    I-Vaccine104517535
is    O
a    O
confidential    O
,    O
population    O
-    O
based    O
,    O
computerized    O
information    O
system    O
that    O
attempts    O
to    O
collect    O
vaccination    O
data    O
about    O
all    O
persons    O
within    O
a    O
geographic    O
area    O
.    O

TA-NIC    B-Vaccine104517535
is    O
a    O
proprietary    O
vaccine    O
in    O
development    O
similar    O
to    O
TA-CD    B-Vaccine104517535
but    O
being    O
used    O
to    O
create    O
human    O
anti    O
-    O
nicotine    O
antibodies    O
in    O
a    O
person    O
to    O
destroy    O
nicotine    O
in    O
the    O
human    O
body    O
so    O
that    O
it    O
is    O
no    O
longer    O
effective    O
.    O

PATH    O
and    O
the    O
World    O
Health    O
Organization    O
,    O
through    O
the    O
Meningitis    O
Vaccine    O
Project    O
,    O
led    O
the    O
development    O
of    O
a    O
vaccine    O
called    O
MenAfriVac    B-Vaccine104517535
to    O
end    O
meningitis    O
A    O
epidemics    O
in    O
sub    O
-    O
Saharan    O
Africa    O
,    O
where    O
450    O
million    O
people    O
in    O
26    O
countries    O
are    O
at    O
risk    O
of    O
the    O
disease    O
.    O

Napoleon    O
Chagnon    O
and    O
James    O
Neel    O
directly    O
and    O
indirectly    O
caused    O
a    O
genocide    O
in    O
the    O
region    O
through    O
the    O
introduction    O
of    O
a    O
live    O
measles    B-Vaccine104517535
vaccine    I-Vaccine104517535
that    O
was    O
insufficiently    O
attenuated    B-Vaccine104517535
.    O

A    O
live    B-Vaccine104517535
vaccine    I-Vaccine104517535
was    O
developed    O
in    O
the    O
Soviet    O
Union    O
in    O
the    O
1930s    O
and    O
first    O
used    O
in    O
humans    O
in    O
1942    O
.    O

Live    B-Vaccine104517535
vaccine    I-Vaccine104517535
:    O
The    O
efficiency    O
of    O
concomitant    O
application    O
of    O
live    O
vaccines    O
has    O
not    O
been    O
fully    O
examined    O
yet    O
.    O

Steffen    O
Mueller    O
at    O
the    O
Stony    O
Brook    O
University    O
designed    O
a    O
live    B-Vaccine104517535
vaccine    I-Vaccine104517535
for    O
polio    O
in    O
which    O
the    O
virus    O
was    O
engineered    O
to    O
have    O
synonymous    O
codons    O
replace    O
naturally    O
occurring    O
ones    O
in    O
the    O
genome    O
.    O

In    O
the    O
early    O
1990s    O
,    O
Minson    O
's    O
group    O
was    O
one    O
of    O
several    O
investigating    O
a    O
novel    O
method    O
of    O
attenuating    B-Vaccine104517535
viruses    O
for    O
use    O
in    O
live    O
vaccines    O
.    O

Zoster    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
a    O
live    B-Vaccine104517535
vaccine    I-Vaccine104517535
that    O
has    O
been    O
shown    O
to    O
reduce    O
the    O
incidence    O
of    O
herpes    O
zoster    O
(    O
known    O
as    O
shingles    O
)    O
The    O
zoster    O
vaccine    O
is    O
,    O
essentially    O
,    O
a    O
larger    O
-    O
than    O
-    O
normal    O
dose    O
of    O
the    O
chickenpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
as    O
both    O
shingles    O
and    O
chickenpox    O
are    O
caused    O
by    O
the    O
same    O
virus    O
,    O
the    O
varicella    O
zoster    O
virus    O
(    O
VZV    O
)    O
.    O

The    O
vaccine    O
contains    O
a    O
minimum    O
of    O
19,400    O
plaque    O
-    O
forming    O
units    O
(    O
PFU    O
)    O
of    O
the    O
Oka    O
/    O
Merck    O
strain    O
of    O
live    O
,    O
attenuated    B-Vaccine104517535
varicella    O
-    O
zoster    O
virus    O
.    O

A    O
large    O
study    O
of    O
nearly    O
800    O
children    O
in    O
the    O
UK    O
with    O
egg    O
allergy    O
,    O
including    O
over    O
250    O
with    O
previous    O
anaphylactic    O
reactions    O
,    O
had    O
zero    O
systemic    O
allergic    O
reactions    O
when    O
given    O
the    O
live    O
attenuated    B-Vaccine104517535
flu    O
vaccine    O
.    O

NeuVax    O
is    O
a    O
peptide    O
vaccine    B-Vaccine104517535
aimed    O
at    O
preventing    O
or    O
delaying    O
the    O
recurrence    O
of    O
breast    O
cancer    O
in    O
cancer    O
survivors    O
who    O
achieve    O
remission    O
after    O
standard    O
of    O
care    O
treatment    O
(    O
e.g.    O
,    O
surgery    O
,    O
radiation    O
,    O
chemotherapy    O
)    O
.    O

This    O
essentially    O
produces    O
a    O
personalised    O
Cancer    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Her    O
research    O
group    O
studies    O
the    O
use    O
of    O
viruses    O
as    O
vectors    O
for    O
introducing    O
new    O
genes    O
into    O
cells    O
,    O
which    O
can    O
be    O
useful    O
for    O
experimental    O
cell    O
biology    O
,    O
for    O
clinical    O
applications    O
such    O
as    O
gene    O
therapy    O
,    O
and    O
as    O
cancer    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

KLH    O
is    O
being    O
tested    O
in    O
a    O
variety    O
of    O
cancer    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
including    O
non    O
-    O
Hodgkins    O
lymphoma    O
,    O
cutaneous    O
melanoma    O
,    O
breast    O
and    O
bladder    O
cancer    O
.    O

It    O
is    O
also    O
required    O
for    O
induction    O
of    O
cytotoxic    O
immunity    O
by    O
vaccination    O
with    O
protein    O
antigens    O
,    O
for    O
example    O
,    O
tumour    B-Vaccine104517535
vaccination    I-Vaccine104517535
.    O

In    O
August    O
2011    O
it    O
was    O
announced    O
that    O
the    O
Center    O
of    O
Molecular    O
Immunology    O
released    O
CimaVax-EGF    B-Vaccine104517535
,    O
the    O
first    O
therapeutic    O
cancer    B-Vaccine104517535
vaccine    I-Vaccine104517535
for    O
lung    O
cancer    O
.    O

Examples    O
of    O
active    O
immunotherapy    O
include    O
cancer    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
adoptive    O
cell    O
transfer    O
,    O
and    O
immunotransplant    O
,    O
which    O
combines    O
vaccination    O
and    O
autologous    O
stem    O
cell    O
transplant    O
.    O

Hepcortespenlisimut-L    B-Vaccine104517535
is    O
an    O
oral    O
immunotherapy    O
that    O
is    O
going    O
through    O
a    O
phase    O
3    O
clinical    O
trial    O
for    O
HCC    O
.    O

The    O
World    O
Health    O
Organization    O
has    O
described    O
VVMs    O
as    O
crucial    O
in    O
the    O
spread    O
of    O
polio    B-Vaccine104517535
vaccination    I-Vaccine104517535
programs    O
.    O

In    O
the    O
1950s    O
Albert    O
Sabin    O
developed    O
the    O
live    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
at    O
the    O
College    O
of    O
Medicine    O
.    O

First    O
oral    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
â€“    O
Albert    O
Sabin    O
(    O
as    O
a    O
researcher    O
at    O
the    O
College    O
of    O
Medicine    O
,    O
and    O
also    O
an    O
alum    O
)    O

Franklin    O
Allen    O
Neva    O
(    O
June    O
8    O
,    O
1922    O
,    O
Cloquet    O
,    O
Minnesota    O
â€“    O
October    O
16    O
,    O
2011    O
,    O
Billings    O
,    O
Montana    O
)    O
was    O
a    O
virologist    O
and    O
physician    O
who    O
discovered    O
Boston    O
exanthem    O
disease    O
,    O
helped    O
isolate    O
rubella    O
virus    O
,    O
and    O
worked    O
with    O
Jonas    O
Salk    O
on    O
the    O
development    O
of    O
the    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Sabin    O
strains    O
,    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
variants    O
developed    O
by    O
Albert    O
Sabin    O

The    O
injectable    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
developed    O
by    O
Jonas    O
Salk    O
was    O
one    O
of    O
the    O
first    O
products    O
mass    O
-    O
produced    O
using    O
cell    O
culture    O
techniques    O
.    O

The    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
developed    O
by    O
Jonas    O
Salk    O
is    O
made    O
available    O
to    O
the    O
public    O
.    O

In    O
the    O
1940s    O
,    O
Jonas    O
Salk    O
used    O
rhesus    O
monkey    O
studies    O
to    O
isolate    O
the    O
most    O
virulent    O
forms    O
of    O
the    O
polio    O
virus    O
,    O
which    O
led    O
to    O
his    O
creation    O
of    O
a    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

The    O
majority    O
of    O
vaccines    O
used    O
worldwide    O
are    O
from    O
reliable    O
local    O
or    O
international    O
manufacturers    O
,    O
and    O
no    O
potency    O
problems    O
have    O
been    O
detected    O
,    O
with    O
the    O
occasional    O
exception    O
of    O
tetanus    O
toxoid    O
and    O
the    O
oral    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
(    O
OPV    O
)    O
.    O

Jonas    O
Salk    O
1934    O
â€“    O
inventor    O
of    O
the    O
Salk    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535

The    O
discovery    O
of    O
SV40    O
revealed    O
that    O
between    O
1955    O
and    O
1963    O
around    O
90%    O
of    O
children    O
and    O
60%    O
of    O
adults    O
in    O
USA    O
were    O
inoculated    O
with    O
SV40-contaminated    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Soon    O
after    O
its    O
discovery    O
,    O
SV40    O
was    O
identified    O
in    O
the    O
oral    O
form    O
of    O
the    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
produced    O
between    O
1955    O
and    O
1961    O
by    O
American    O
Home    O
Products    O
(    O
dba    O
Lederle    O
)    O
.    O

The    O
hospital    O
has    O
been    O
a    O
significant    O
player    O
in    O
a    O
variety    O
of    O
historic    O
medical    O
breakthroughs    O
,    O
most    O
prominently    O
Dr.    O
Albert    O
Sabin    O
's    O
development    O
of    O
the    O
oral    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
which    O
went    O
into    O
use    O
in    O
the    O
United    O
States    O
in    O
1960    O
.    O

The    O
organization    O
initially    O
focused    O
on    O
the    O
rehabilitation    O
of    O
victims    O
of    O
paralytic    O
polio    O
,    O
and    O
supported    O
the    O
work    O
of    O
Jonas    O
Salk    O
and    O
others    O
that    O
led    O
to    O
the    O
development    O
of    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

As    O
he    O
walked    O
in    O
the    O
door    O
,    O
his    O
wife    O
,    O
Joyce    O
,    O
informed    O
him    O
that    O
the    O
children    O
had    O
gotten    O
their    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
that    O
day    O
.    O

Hilary    O
Koprowski    O
,    O
Polish    O
virologist    O
and    O
immunologist    O
,    O
inventor    O
of    O
the    O
world    O
's    O
first    O
effective    O
live    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535

Albert    O
Sabin    O
,    O
a    O
Polish    O
-    O
American    O
medical    O
researcher    O
,    O
best    O
known    O
for    O
developing    O
the    O
oral    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
which    O
has    O
played    O
a    O
key    O
role    O
in    O
nearly    O
eradicating    O
the    O
disease    O

MRC-5    O
cells    O
are    O
used    O
to    O
produce    O
several    O
vaccines    O
including    O
MMR    B-Vaccine104517535
,    O
Varicella    B-Vaccine104517535
and    O
Polio    B-Vaccine104517535
.    O

Moore    O
also    O
points    O
to    O
Jonas    O
Salk    O
,    O
who    O
developed    O
and    O
refused    O
to    O
patent    O
a    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

The    O
entire    O
family    O
also    O
participated    O
in    O
the    O
Sabin    B-Vaccine104517535
vaccine    I-Vaccine104517535
program    O
to    O
prevent    O
polio    O
.    O

Jonas    O
Salk    O
â€“    O
physician    O
,    O
inventor    O
of    O
first    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535

He    O
worked    O
with    O
Dr.    O
Jonas    O
Salk    O
to    O
develop    O
the    O
first    O
effective    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Hilary    O
Koprowski    O
(    O
5    O
December    O
191611    O
April    O
2013    O
)    O
was    O
a    O
Polish    O
virologist    O
and    O
immunologist    O
active    O
in    O
the    O
United    O
States    O
,    O
and    O
inventor    O
of    O
the    O
world    O
's    O
first    O
effective    O
live    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Here    O
he    O
began    O
his    O
polio    O
experiments    O
,    O
which    O
ultimately    O
led    O
to    O
the    O
creation    O
of    O
the    O
first    O
oral    B-Vaccine104517535
polio    I-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Polio    B-Vaccine104517535
vaccine    I-Vaccine104517535

She    O
is    O
known    O
for    O
her    O
contribution    O
to    O
the    O
development    O
of    O
safety    O
testing    O
procedures    O
for    O
polio    B-Vaccine104517535
vaccine    I-Vaccine104517535
used    O
in    O
the    O
United    O
Kingdom    O
.    O

Anti-idiotypic    B-Vaccine104517535
vaccines    I-Vaccine104517535
comprise    O
antibodies    O
that    O
have    O
three    O
-    O
dimensional    O
immunogenic    O
regions    O
,    O
designated    O
idiotopes    O
,    O
that    O
consist    O
of    O
protein    O
sequences    O
that    O
bind    O
to    O
cell    O
receptors    O
.    O

He    O
proposeed    O
that    O
the    O
swine    B-Vaccine104517535
flu    I-Vaccine104517535
vaccination    I-Vaccine104517535
campaign    I-Vaccine104517535
of    O
2009    O
was    O
also    O
used    O
to    O
mark    O
people    O
with    O
those    O
"    O
chips    O
"    O
and    O
denies    O
the    O
existence    O
of    O
HIV    O
.    O

The    O
CDC    O
distributed    O
a    O
vaccine    B-Vaccine104517535
for    O
the    O
novel    O
flu    O
strain    O
.    O
using    O
mechanisms    O
already    O
in    O
place    O
for    O
its    O
Vaccines    O
for    O
Children    O
(    O
VFC    O
)    O
program    O
.    O

About    O
40%    O
of    O
Canadians    O
have    O
been    O
immunized    B-Vaccine104517535
against    I-Vaccine104517535
H1N1    I-Vaccine104517535
since    O
a    O
national    O
vaccination    O
campaign    O
began    O
in    O
October    O
,    O
with    O
Canada    O
among    O
the    O
countries    O
in    O
the    O
world    O
leading    O
in    O
the    O
percentage    O
of    O
the    O
population    O
that    O
has    O
been    O
vaccinated    O
.    O

In    O
August    O
2011    O
it    O
was    O
announced    O
that    O
the    O
Center    O
of    O
Molecular    O
Immunology    O
released    O
CimaVax-EGF    B-Vaccine104517535
,    O
the    O
first    O
therapeutic    O
cancer    B-Vaccine104517535
vaccine    I-Vaccine104517535
for    O
lung    O
cancer    O
.    O

CYT006-AngQb    B-Vaccine104517535
was    O
an    O
investigational    O
vaccine    O
against    O
angiotensin    O
II    O
,    O
designed    O
to    O
lower    O
blood    O
pressure    O
.    O

1992    O
First    O
vaccine    B-Vaccine104517535
for    O
hepatitis    O
A    O

The    O
pneumococcal    B-Vaccine104517535
conjugate    I-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
the    O
rotavirus    B-Vaccine104517535
vaccine    I-Vaccine104517535
and    O
the    O
Hepatitis    B-Vaccine104517535
A    I-Vaccine104517535
vaccine    I-Vaccine104517535
are    O
yet    O
to    O
be    O
introduced    O
to    O
the    O
National    O
Immunisation    O
Program    O
.    O

Hepatitis    B-Vaccine104517535
A    I-Vaccine104517535
vaccine    I-Vaccine104517535

In    O
the    O
case    O
of    O
infectious    O
rhinitis    O
,    O
vaccination    O
against    O
influenza    B-Vaccine104517535
viruses    I-Vaccine104517535
,    O
adenoviruses    B-Vaccine104517535
,    O
measles    O
,    O
rubella    O
,    O
"    O
Streptococcus    O
pneumoniae    O
"    O
,    O
"Haemophilus    B-Vaccine104517535
influenzae"    I-Vaccine104517535
,    O
diphtheria    B-Vaccine104517535
,    O
"Bacillus    B-Vaccine104517535
anthracis"    I-Vaccine104517535
,    O
and    O
"Bordetella    B-Vaccine104517535
pertussis"    I-Vaccine104517535
may    O
help    O
prevent    O
it    O
.    O

Pertussis    B-Vaccine104517535
vaccine    I-Vaccine104517535

Pertussis    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
such    O
as    O
in    O
DPT    B-Vaccine104517535
vaccine    I-Vaccine104517535

Tetanus    B-Vaccine104517535
vaccine    I-Vaccine104517535
(    O
such    O
as    O
in    O
the    O
DPT    B-Vaccine104517535
vaccine    I-Vaccine104517535
)    O

It    O
is    O
possible    O
that    O
Unit    O
731    O
's    O
methods    O
and    O
objectives    O
were    O
also    O
followed    O
in    O
Indonesia    O
,    O
in    O
a    O
case    O
of    O
failed    O
experiment    O
designed    O
to    O
validate    O
a    O
conjured    O
tetanus    B-Vaccine104517535
toxoid    I-Vaccine104517535
vaccine    O
.    O

Immunization    O
(    O
which    O
is    O
impermanent    O
and    O
must    O
be    O
repeated    O
periodically    O
)    O
instead    O
utilizes    O
the    O
less    O
deadly    O
toxoid    O
derived    O
from    O
the    O
toxin    O
,    O
as    O
in    O
the    O
tetanus    B-Vaccine104517535
vaccine    I-Vaccine104517535
and    O
some    O
combination    O
vaccines    O
(    O
such    O
as    O
DTP    B-Vaccine104517535
)    O
.    O

Born    O
:    O
Henri    O
Laborit    O
,    O
French    O
physician    O
and    O
researcher    O
,    O
leading    O
researcher    O
in    O
neurology    O
and    O
evolutionary    O
psychology    O
,    O
in    O
Hanoi    O
,    O
French    O
Indochina    O
(    O
d.    O
1995    O
)    O
;    O
Nusret    O
FiÅŸek    O
,    O
Turkish    O
physician    O
,    O
lead    O
researcher    O
on    O
the    O
development    O
of    O
the    O
tetanus    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
in    O
Sivas    O
,    O
Turkey    O
(    O
d.    O
1990    O
)    O
;    O
Donald    O
Greene    O
,    O
Canadian    O
academic    O
,    O
leading    O
literary    O
critic    O
on    O
18th    O
-    O
century    O
English    O
literature    O
including    O
Samuel    O
Johnson    O
,    O
in    O
Moose    O
Jaw    O
,    O
Saskatchewan    O
(    O
d.    O
1997    O
)    O

It    O
is    O
possible    O
that    O
Mochtar    O
was    O
a    O
scapegoat    O
for    O
a    O
failed    O
Japanese    O
experiment    O
designed    O
to    O
validate    O
a    O
conjured    O
tetanus    B-Vaccine104517535
toxoid    I-Vaccine104517535
vaccine    O
for    O
their    O
troops    O
.    O

The    O
success    O
of    O
the    O
chickenpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
demonstrates    O
that    O
a    O
live    O
and    O
appropriately    O
attenuated    O
Î±-herpesvirus    O
may    O
be    O
used    O
to    O
safely    O
control    O
human    O
disease    O
.    O

Varicella    B-Vaccine104517535
vaccine    I-Vaccine104517535

Zoster    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
a    O
live    B-Vaccine104517535
vaccine    I-Vaccine104517535
that    O
has    O
been    O
shown    O
to    O
reduce    O
the    O
incidence    O
of    O
herpes    O
zoster    O
(    O
known    O
as    O
shingles    O
)    O
The    O
zoster    O
vaccine    O
is    O
,    O
essentially    O
,    O
a    O
larger    O
-    O
than    O
-    O
normal    O
dose    O
of    O
the    O
chickenpox    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
as    O
both    O
shingles    O
and    O
chickenpox    O
are    O
caused    O
by    O
the    O
same    O
virus    O
,    O
the    O
varicella    O
zoster    O
virus    O
(    O
VZV    O
)    O
.    O

Varicella    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
a    O
vaccine    O
against    O
chickenpox    O
---    O
first    O
dose    O

MRC-5    O
cells    O
are    O
used    O
to    O
produce    O
several    O
vaccines    O
including    O
MMR    B-Vaccine104517535
,    O
Varicella    B-Vaccine104517535
and    O
Polio    B-Vaccine104517535
.    O

Ty21a    B-Vaccine104517535
and    O
ViCPS    B-Vaccine104517535
vaccines    O

Conjugate    B-Vaccine104517535
are    O
being    O
developed    O
as    O
vaccines    O
or    O
are    O
already    O
being    O
used    O
without    O
a    O
priori    O
knowledge    O
.    O

NicVAX    B-Vaccine104517535
is    O
an    O
experimental    O
conjugate    B-Vaccine104517535
vaccine    I-Vaccine104517535
intended    O
to    O
reduce    O
or    O
eliminate    O
physical    O
dependence    O
to    O
nicotine    O
.    O

Since    O
lipids    O
and    O
nucleic    O
acids    O
are    O
non    O
-    O
immunogenic    O
haptens    O
,    O
they    O
require    O
conjugation    B-Vaccine104517535
with    O
an    O
epitope    O
such    O
as    O
a    O
protein    O
or    O
polysaccharide    O
before    O
they    O
can    O
evoke    O
an    O
immunologic    O
response    O
.    O

LICR    O
SÃ£o    O
Paulo    O
Branch    O
Director    O
,    O
and    O
co    O
-    O
founder    O
of    O
the    O
Ludwig    O
/    O
McGill    O
Cohort    O
,    O
Dr.    O
Luisa    O
L.    O
Villa    O
,    O
was    O
the    O
lead    O
author    O
of    O
the    O
first    O
study    O
to    O
show    O
efficacy    O
of    O
Merck    O
â€™s    O
HPV    O
vaccine    O
,    O
Gardasil    B-Vaccine104517535
.    O

In    O
the    O
early    O
21st    O
century    O
,    O
the    O
vaccine    O
market    O
greatly    O
improved    O
with    O
the    O
approval    O
of    O
the    O
vaccine    O
Prevnar    B-Vaccine104517535
,    O
along    O
with    O
a    O
small    O
number    O
of    O
other    O
high    O
-    O
priced    O
blockbuster    O
vaccines    O
,    O
such    O
as    O
Gardasil    B-Vaccine104517535
and    O
Pediarix    O
,    O
which    O
each    O
had    O
sales    O
revenues    O
of    O
over    O
$    O
1    O
billion    O
in    O
2008    O
.    O

The    O
choristers    O
are    O
featured    O
performers    O
at    O
the    O
Royal    O
Albert    O
Hall    O
for    O
the    O
launch    O
of    O
the    O
anti    O
-    O
cervical    O
cancer    O
vaccine    O
,    O
Gardasil    B-Vaccine104517535
(    O
October    O
17    O
,    O
2012    O
)    O

In    O
2006    O
,    O
plans    O
were    O
announced    O
for    O
a    O
research    O
center    O
operated    O
by    O
the    O
University    O
of    O
Louisville    O
to    O
be    O
located    O
at    O
the    O
Mitchell    O
Memorial    O
Cancer    O
Center    O
,    O
a    O
part    O
of    O
the    O
Owensboro    O
Medical    O
Health    O
System    O
,    O
to    O
study    O
how    O
to    O
make    O
the    O
first    O
ever    O
human    O
papilloma    O
virus    O
vaccine    O
,    O
called    O
Gardasil    B-Vaccine104517535
,    O
from    O
tobacco    O
plants    O
.    O

Human    B-Vaccine104517535
papillomavirus    I-Vaccine104517535
vaccine    I-Vaccine104517535
(    O
Gardasil    B-Vaccine104517535
and    O
Cervarix    B-Vaccine104517535
)    O
decreases    O
the    O
risk    O
of    O
developing    O
cervical    O
cancer    O
.    O

A    O
hepatitis    B-Vaccine104517535
C    I-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
a    O
vaccine    O
capable    O
of    O
protecting    O
against    O
hepatitis    O
C    O
,    O
is    O
not    O
available    O
.    O

A    O
Cytomegalovirus    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
a    O
vaccine    O
to    O
prevent    O
cytomegalovirus    O
(    O
CMV    O
)    O
infection    O
or    O
to    O
prevent    O
it    O
re    O
-    O
activation    O
in    O
those    O
who    O
are    O
already    O
infected    O
.    O

Typhoid    B-Vaccine104517535
vaccine    I-Vaccine104517535

The    O
Texas    O
Department    O
of    O
State    O
Health    O
Services    O
sent    O
water    O
and    O
sanitation    O
teams    O
to    O
the    O
areas    O
affected    O
by    O
the    O
storm    O
,    O
as    O
well    O
as    O
3,000    O
shots    O
of    O
typhoid    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Modified    B-Vaccine104517535
vaccinia    I-Vaccine104517535
Ankara    I-Vaccine104517535
,    O
a    O
virus    O
modified    O
to    O
carry    O
vaccines    O

The    O
vaccine    O
works    O
with    O
a    O
combined    O
DNA    O
vaccine    O
and    O
MVA    O
(    O
modified    B-Vaccine104517535
vaccinia    I-Vaccine104517535
Ankara    I-Vaccine104517535
)    O
vaccine    O
both    O
of    O
which    O
lead    O
to    O
the    O
insertion    O
of    O
genes    O
into    O
primate    O
DNA    O
which    O
leads    O
to    O
foreign    O
protein    O
expression    O
.    O

Tuberculosis    B-Vaccine104517535
vaccine    I-Vaccine104517535
by    O
Albert    O
Calmette    O
and    O
Camille    O
GuÃ©rin    O
in    O
1921    O
(    O
BCG    O
)    O
.    O

A    O
peptide    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
any    O
peptide    O
which    O
serves    O
to    O
immunize    O
an    O
organism    O
against    O
a    O
pathogen    O
.    O

In    O
the    O
case    O
of    O
infectious    O
rhinitis    O
,    O
vaccination    O
against    O
influenza    B-Vaccine104517535
viruses    I-Vaccine104517535
,    O
adenoviruses    B-Vaccine104517535
,    O
measles    O
,    O
rubella    O
,    O
"    O
Streptococcus    O
pneumoniae    O
"    O
,    O
"Haemophilus    B-Vaccine104517535
influenzae"    I-Vaccine104517535
,    O
diphtheria    B-Vaccine104517535
,    O
"Bacillus    B-Vaccine104517535
anthracis"    I-Vaccine104517535
,    O
and    O
"Bordetella    B-Vaccine104517535
pertussis"    I-Vaccine104517535
may    O
help    O
prevent    O
it    O
.    O

An    O
adenovirus    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
a    O
vaccine    O
against    O
Adenovirus    O
.    O

Tcelna    B-Vaccine104517535
is    O
currently    O
under    O
active    O
research    O
by    O
Opexa    O
,    O
showing    O
promising    O
results    O
.    O

Plant    B-Vaccine104517535
expressed    I-Vaccine104517535
vaccine    I-Vaccine104517535
or    O
project    B-Vaccine104517535
GreenVax    I-Vaccine104517535

DA2PPC    B-Vaccine104517535
Vaccine    I-Vaccine104517535

Scarlet    B-Vaccine104517535
fever    I-Vaccine104517535
serum    I-Vaccine104517535
was    O
used    O
beginning    O
in    O
November    O
1900    O
after    O
its    O
development    O
in    O
the    O
Sero    O
-    O
Therapeutic    O
Laboratory    O
of    O
Rudolph    O
Hospital    O

They    O
agree    O
and    O
have    O
the    O
other    O
boys    O
stay    B-Vaccine104517535
at    I-Vaccine104517535
Kenny's    I-Vaccine104517535
house    I-Vaccine104517535
.    O

Based    O
on    O
studies    O
in    O
animal    O
models    O
,    O
theoretical    O
concerns    O
have    O
been    O
raised    O
about    O
a    O
possible    O
link    O
between    O
schizophrenia    O
and    O
maternal    O
immune    O
response    O
activated    O
by    O
virus    O
antigens    O
;    O
a    O
2009    O
review    O
concluded    O
that    O
there    O
was    O
insufficient    O
evidence    O
to    O
recommend    O
routine    O
use    O
of    O
trivalent    B-Vaccine104517535
influenza    I-Vaccine104517535
vaccine    I-Vaccine104517535
during    O
the    O
first    O
trimester    O
of    O
pregnancy    O
,    O
but    O
that    O
the    O
vaccine    O
was    O
still    O
recommended    O
outside    O
the    O
first    O
trimester    O
and    O
in    O
special    O
circumstances    O
such    O
as    O
pandemics    O
or    O
in    O
women    O
with    O
certain    O
other    O
conditions    O
.    O

Medicago    O
Inc.    O
â€“    O
Pre    O
-    O
clinical    O
trials    O
of    O
Influenza    B-Vaccine104517535
vaccine    I-Vaccine104517535
made    O
in    O
transiently    O
infected    O
"    O
Nicotiana    O
benthamiana    O
"    O
(    O
relative    O
of    O
tobacco    O
)    O
plants    O
in    O
greenhouses    O
Medicago    O
has    O
a    O
system    O
for    O
pharming    O
in    O
alfalfa    O
that    O
their    O
website    O
says    O
is    O
"    O
not    O
suited    O
for    O
the    O
production    O
of    O
vaccines    O
"    O

Influenza    B-Vaccine104517535
vaccine    I-Vaccine104517535

In    O
2009    O
Kopacz    O
gained    O
some    O
degree    O
of    O
international    O
fame    O
by    O
requesting    O
pharmaceutical    O
companies    O
to    O
present    O
the    O
advantages    O
of    O
swine    O
flu    O
vaccines    B-Vaccine104517535
,    O
and    O
demanding    O
they    O
take    O
full    O
responsibility    O
for    O
the    O
side    O
effects    O
.    O

In    O
June    O
2006    O
,    O
the    O
National    O
Institutes    O
of    O
Health    O
(    O
NIH    O
)    O
began    O
enrolling    O
participants    O
in    O
a    O
Phase    O
1    O
H5N1    O
study    O
of    O
an    O
intranasal    O
influenza    B-Vaccine104517535
vaccine    I-Vaccine104517535
candidate    O
based    O
on    O
MedImmune    O
's    O
live,    B-Vaccine104517535
attenuated    I-Vaccine104517535
vaccine    I-Vaccine104517535
technology    I-Vaccine104517535
.    O

Due    O
to    O
the    O
H5N1    O
pandemic    O
threat    O
,    O
research    O
into    O
using    O
cell    O
culture    O
for    O
influenza    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
being    O
funded    O
by    O
the    O
United    O
States    O
government    O
.    O

Influenza    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

In    O
September    O
2017    O
it    O
was    O
announced    O
that    O
Janssen    O
teamed    O
up    O
with    O
the    O
Biomedical    O
Advanced    O
Research    O
and    O
Development    O
Authority    O
(    O
BARDA    O
)    O
,    O
a    O
unit    O
of    O
the    O
U.S.    O
Department    O
of    O
Health    O
and    O
Human    O
Services    O
,    O
to    O
create    O
pandemic    O
flu    B-Vaccine104517535
vaccines    I-Vaccine104517535
.    O

South    O
Korea    O
ranked    O
highest    O
in    O
influenza    B-Vaccine104517535
vaccination    I-Vaccine104517535
in    O
Asia    O
at    O
311    O
vaccines    O
per    O
1,000    O
people    O
.    O

On    O
28    O
September    O
2009    O
Johnson    O
&    O
Johnson    O
bought    O
18%    O
stake    O
in    O
Crucell    O
for    O
â‚¬    O
302    O
million    O
in    O
order    O
to    O
collaborate    O
on    O
the    O
development    O
of    O
a    O
flu    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

The    O
2009    B-Vaccine104517535
flu    I-Vaccine104517535
pandemic    I-Vaccine104517535
vaccines    I-Vaccine104517535
are    O
the    O
set    O
of    O
influenza    B-Vaccine104517535
vaccine    I-Vaccine104517535
that    O
have    O
been    O
developed    O
to    O
protect    O
against    O
the    O
pandemic    O
H1N1/09    O
virus    O
.    O

A    O
number    O
of    O
measures    O
decrease    O
the    O
risk    O
of    O
otitis    O
media    O
including    O
pneumococcal    O
and    O
influenza    B-Vaccine104517535
vaccination    I-Vaccine104517535
,    O
exclusive    O
breastfeeding    O
for    O
the    O
first    O
six    O
months    O
of    O
life    O
,    O
and    O
avoiding    O
tobacco    O
smoke    O
.    O

Influenza    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
recommended    O
annually    O
for    O
all    O
children    O
.    O

Influenza    B-Vaccine104517535
vaccines    I-Vaccine104517535
,    O
also    O
known    O
as    O
flu    B-Vaccine104517535
shots    I-Vaccine104517535
or    O
flu    B-Vaccine104517535
jabs    I-Vaccine104517535
,    O
are    O
vaccines    O
that    O
protect    O
against    O
infection    O
by    O
influenza    O
virus    O
.    O

The    O
generosity    O
of    O
state    O
citizens    O
has    O
gained    O
respect    O
;    O
the    O
heavily    O
-    O
reported    O
influenza    B-Vaccine104517535
vaccine    I-Vaccine104517535
shortage    O
of    O
fall    O
2004    O
did    O
not    O
strike    O
the    O
state    O
as    O
hard    O
as    O
elsewhere    O
since    O
many    O
people    O
willingly    O
gave    O
up    O
injections    O
for    O
others    O
.    O

However    O
,    O
new    O
strains    O
that    O
escape    O
immunity    O
induced    O
by    O
vaccines    O
may    O
evolve    O
;    O
for    O
example    O
,    O
an    O
updated    O
influenza    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
needed    O
each    O
year    O
.    O

Health    O
authorities    O
implement    O
public    O
health    O
measures    O
for    O
all    O
airport    O
passengers    O
and    O
the    O
vaccination    O
of    O
health    O
care    O
workers    O
with    O
seasonal    O
influenza    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

The    O
vaccination    B-Vaccine104517535
program    O
,    O
enacted    O
at    O
a    O
cost    O
of    O
$    O
135    O
million    O
,    O
was    O
plagued    O
by    O
delays    O
and    O
public    O
relations    O
problems    O
.    O

Rotavirus    B-Vaccine104517535
vaccine    I-Vaccine104517535

In    O
the    O
1990s    O
and    O
2000s    O
,    O
Dr.    O
Paul    O
Offit    O
,    O
a    O
professor    O
of    O
Pediatrics    O
at    O
the    O
School    O
of    O
Medicine    O
and    O
Children    O
's    O
Hospital    O
of    O
Philadelphia    O
,    O
lead    O
the    O
scientific    O
advances    O
behind    O
the    O
modern    O
RotaTeq    B-Vaccine104517535
vaccine    O
for    O
infectious    O
childhood    O
diarrhea    O
.    O

Two    O
rotavirus    B-Vaccine104517535
vaccine    I-Vaccine104517535
against    O
Rotavirus    O
A    O
infection    O
are    O
safe    O
and    O
effective    O
in    O
children    O
:    O
Rotarix    O
by    O
GlaxoSmithKline    O
and    O
RotaTeq    O
by    O
Merck    O
.    O

In    O
1998    O
,    O
a    O
rotavirus    B-Vaccine104517535
vaccine    I-Vaccine104517535
was    O
licensed    O
for    O
use    O
in    O
the    O
United    O
States    O
.    O

A    O
live    O
attenuated    O
"    O
Listeria    O
monocytogenes    O
"    O
cancer    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
ADXS11-001    B-Vaccine104517535
,    O
is    O
under    O
development    O
as    O
a    O
possible    O
treatment    O
for    O
cervical    O
carcinoma    O
.    O

NicVAX    B-Vaccine104517535
is    O
an    O
experimental    O
conjugate    B-Vaccine104517535
vaccine    I-Vaccine104517535
intended    O
to    O
reduce    O
or    O
eliminate    O
physical    O
dependence    O
to    O
nicotine    O
.    O

Historical    B-Vaccine104517535
annual    I-Vaccine104517535
reformulations    I-Vaccine104517535
of    I-Vaccine104517535
the    I-Vaccine104517535
influenza    I-Vaccine104517535
vaccine    I-Vaccine104517535
are    O
listed    O
in    O
a    O
separate    O
article    O
.    O

Also    O
called    O
APC    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

The    O
strain    O
of    O
mumps    O
virus    O
that    O
was    O
used    O
to    O
develop    O
the    O
vaccine    O
was    O
given    O
the    O
name    O
"    O
Jeryl    B-Vaccine104517535
Lynn    I-Vaccine104517535
"    O
after    O
the    O
little    O
girl    O
,    O
Jeryl    O
Lynn    O
Hilleman    O
.    O

A    O
Schistosomiasis    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
a    O
vaccine    O
against    O
Schistosomiasis    O
(    O
also    O
known    O
as    O
bilharzia    B-Vaccine104517535
,    O
bilharziosis    B-Vaccine104517535
or    O
snail    B-Vaccine104517535
fever    I-Vaccine104517535
)    O
,    O
a    O
parasitic    O
disease    O
caused    O
by    O
several    O
species    O
of    O
fluke    O
of    O
the    O
genus    O
"    O
Schistosoma    O
"    O
.    O

prof    O
Francis    O
Home    O
FRSE    O
FRCPE    O
(    O
17    O
November    O
1719    O
in    O
Eccles    O
,    O
Berwickshire    O
â€“    O
15    O
February    O
1813    O
)    O
was    O
a    O
Scottish    O
physician    O
,    O
and    O
the    O
first    O
Professor    O
of    O
Materia    O
Medica    O
at    O
the    O
University    O
of    O
Edinburgh    O
,    O
known    O
to    O
make    O
the    O
first    O
attempt    O
to    O
vaccinate    B-Vaccine104517535
against    I-Vaccine104517535
measles    I-Vaccine104517535
,    O
in    O
1758    O
.    O

Measles    B-Vaccine104517535
vaccine    I-Vaccine104517535

Physician    O
Francis    O
Home    O
makes    O
the    O
first    O
attempt    O
to    O
deliver    O
a    O
measles    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

One    O
of    O
the    O
most    O
important    O
findings    O
was    O
that    O
a    O
new    O
measles    B-Vaccine104517535
vaccine    I-Vaccine104517535
used    O
in    O
low    O
-    O
income    O
countries    O
was    O
associated    O
with    O
a    O
two    O
-    O
fold    O
increase    O
in    O
mortality    O
among    O
girls    O
.    O

Pandemrix    B-Vaccine104517535
,    O
made    O
by    O
GlaxoSmithKline    O
(    O
GSK    O
)    O
,    O
and    O
Focetria    O
,    O
made    O
by    O
Novartis    O
were    O
approved    O
by    O
the    O
European    O
Medicines    O
Agency    O
on    O
25    O
September    O
2009    O
,    O
and    O
Celvapan    O
,    O
made    O
by    O
Baxter    O
was    O
approved    O
the    O
following    O
week    O
.    O

In    O
2010    O
,    O
The    O
Swedish    O
Medical    O
Products    O
Agency    O
(    O
MPA    O
)    O
and    O
The    O
Finnish    O
National    O
Institute    O
for    O
Health    O
and    O
Welfare    O
(    O
THL    O
)    O
received    O
reports    O
from    O
Swedish    O
and    O
Finnish    O
health    O
care    O
professionals    O
regarding    O
narcolepsy    O
as    O
suspected    O
adverse    O
reaction    O
following    O
Pandemrix    B-Vaccine104517535
flu    O
vaccination    O
.    O

Rabies    B-Vaccine104517535
vaccine    I-Vaccine104517535

Some    O
injuries    O
,    O
including    O
animal    O
bites    O
,    O
are    O
also    O
treated    O
with    O
antibiotics    O
,    O
irrigation    O
,    O
and    O
rabies    B-Vaccine104517535
prophylaxis    I-Vaccine104517535
.    O

Rabies    B-Vaccine104517535
vaccine    I-Vaccine104517535
by    O
Louis    O
Pasteur    O
and    O
Ã‰mile    O
Roux    O
in    O
1885    O
.    O

During    O
his    O
administration    O
rabies    B-Vaccine104517535
vaccination    I-Vaccine104517535
was    O
established    O
,    O
yellow    O
fever    O
along    O
the    O
Gulf    O
Coast    O
,    O
and    O
bubonic    O
plague    O
at    O
Mazatlan    O
were    O
brought    O
under    O
control    O
.    O

The    O
Queen    O
Saovabha    O
Memorial    O
Institute    O
(    O
QSMI    O
)    O
(    O
"    O
Sathan    O
Saovabha    O
"    O
)    O
in    O
Bangkok    O
,    O
Thailand    O
,    O
is    O
a    O
institute    O
that    O
specialises    O
in    O
the    O
husbandry    O
of    O
venomous    O
snakes    O
,    O
the    O
extraction    O
and    O
research    O
of    O
snake    O
venom    O
,    O
and    O
vaccines    O
,    O
especially    O
rabies    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Possibly    O
,    O
this    O
societal    O
shift    O
can    O
be    O
attributed    O
to    O
discovery    O
of    O
the    O
rabies    B-Vaccine104517535
vaccine    I-Vaccine104517535
in    O
1869    O
.    O

1885    O
â€“    O
Louis    O
Pasteur    O
and    O
Emile    O
Roux    O
develop    O
the    O
first    O
rabies    B-Vaccine104517535
vaccine    I-Vaccine104517535
and    O
use    O
it    O
on    O
Joseph    O
Meister    O
.    O

Ty21a    B-Vaccine104517535
and    O
ViCPS    B-Vaccine104517535
vaccines    O

HspE7    B-Vaccine104517535
is    O
an    O
investigational    O
therapeutic    O
vaccine    O
candidate    O
being    O
developed    O
by    O
Nventa    O
Biopharmaceuticals    O
for    O
the    O
treatment    O
of    O
precancerous    O
and    O
cancerous    O
lesions    O
caused    O
by    O
the    O
human    O
papillomavirus    O
(    O
HPV    O
)    O
.    O

72F    B-Vaccine104517535
fusion    I-Vaccine104517535
protein    I-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
a    O
candidate    O
tuberculosis    B-Vaccine104517535
vaccine    I-Vaccine104517535
created    O
by    O
Statens    O
Serum    O
Institut    O
(    O
SSI    O
)    O
.    O

Dukoral    B-Vaccine104517535

Oral    B-Vaccine104517535
cholera    I-Vaccine104517535
vaccines    I-Vaccine104517535
have    O
the    O
potential    O
to    O
shorten    O
cholera    O
outbreaks    O
,    O
and    O
hence    O
reduce    O
the    O
morbidity    O
and    O
mortality    O
associated    O
with    O
outbreaks    O
have    O
not    O
been    O
deployed    O
in    O
Sierra    O
Leone    O
.    O

The    O
oral    B-Vaccine104517535
cholera    I-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
while    O
effective    O
for    O
cholera    O
,    O
is    O
of    O
questionable    O
use    O
for    O
traveler    O
's    O
diarrhea    O
.    O

The    O
oral    B-Vaccine104517535
cholera    I-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
while    O
effective    O
for    O
prevention    O
of    O
cholera    O
,    O
is    O
of    O
questionable    O
use    O
for    O
prevention    O
of    O
TD    O
.    O

With    O
the    O
exception    O
of    O
Yellow    B-Vaccine104517535
fever    I-Vaccine104517535
vaccine    I-Vaccine104517535
neither    O
vaccines    O
nor    O
experimental    O
vaccines    O
are    O
readily    O
available    O
.    O

Yellow    B-Vaccine104517535
fever    I-Vaccine104517535
vaccine    I-Vaccine104517535

sarcoplasmic    O
reticulum    O
-    O
satellite    O
DNA    O
-    O
scientific    O
notation    O
-    O
SDS    O
-    O
PAGE    O
-    O
second    O
messenger    O
-    O
second    O
messenger    O
system    O
-    O
secondary    O
structure    O
-    O
secretin    O
-    O
selectin    O
-    O
sensory    O
receptor    O
-    O
sequence    O
(    O
biology    O
)    O
-    O
sequence    O
homology    O
-    O
sequence    O
motif    O
-    O
sequencing    O
-    O
serine    O
-    O
serotonin    O
-    O
serotonin    O
receptor    O
-    O
serpin    O
-    O
sexual    O
reproduction    O
-    O
SH3    O
domain    O
-    O
SI    O
-    O
sigma    O
factor    O
-    O
signal    O
peptide    O
-    O
signal    O
recognition    O
particle    O
-    O
signal    O
sequence    O
-    O
signal    O
transduction    O
-    O
sincalide    O
-    O
skeleton    O
-    O
skin    O
-    O
smooth    O
ER    O
-    O
sodium    O
channel    O
-    O
sodium    O
-    O
hydrogen    O
antiporter    O
-    O
soluble    O
-    O
solution    O
-    O
solvation    O
-    O
solvent    O
-    O
somatomedin    O
-    O
somatomedin    O
receptor    O
-    O
somatostatin    O
-    O
somatostatin    O
receptor    O
-    O
somatotropin    O
-    O
somatotropin    O
receptor    O
-    O
somatotropin    O
-    O
releasing    O
hormone    O
-    O
somatropin    O
-    O
sp1    O
transcription    O
factor    O
-    O
spectrin    O
-    O
spectroscopy    O
-    O
src    O
gene    O
-    O
src    O
-    O
family    O
kinase    O
-    O
SSRI    O
-    O
starch    O
-    O
stem    O
cell    O
-    O
stereochemistry    O
-    O
steroid    O
17alpha    O
-    O
monooxygenase    O
-    O
steroid    O
21-monooxygenase    O
-    O
steroid    O
receptor    O
-    O
stimulatory    O
gs    O
G    O
-    O
protein    O
-    O
stoichiometry    O
-    O
structural    O
biology    O
-    O
structural    O
domain    O
-    O
Structural    O
formula    O
-    O
structural    O
motif    O
-    O
substance    O
P    O
-    O
substrate    O
-    O
sugar    O
-    O
sulfur    O
-    O
supercoil    O
-    O
superfamily    O
-    O
superoxide    O
-    O
surface    O
immunoglobulin    O
-    O
surface    O
plasmon    O
resonance    O
-    O
suspension    O
(    O
chemistry    O
)    O
-    O
synapse    O
-    O
synthetic    B-Vaccine104517535
vaccine    I-Vaccine104517535
-    O
systems    O
biology    O
-    O

A    O
direct    O
approach    O
to    O
transfection    O
is    O
the    O
gene    B-Vaccine104517535
gun    I-Vaccine104517535
,    O
where    O
the    O
DNA    O
is    O
coupled    O
to    O
a    O
nanoparticle    O
of    O
an    O
inert    O
solid    O
(    O
commonly    O
gold    O
)    O
,    O
which    O
is    O
then    O
"    O
shot    O
"    O
directly    O
into    O
the    O
target    O
cell    O
's    O
nucleus    O
.    O

In    O
1995    O
,    O
Monsanto    O
introduced    O
"    O
Roundup    O
Ready    O
"    O
(    O
RR    O
)    O
soybeans    O
that    O
have    O
had    O
a    O
copy    O
of    O
a    O
gene    O
from    O
the    O
bacterium    O
,    O
"    O
Agrobacterium    O
"    O
sp    O
.    O
strain    O
CP4    O
,    O
inserted    O
,    O
by    O
means    O
of    O
a    O
gene    B-Vaccine104517535
gun    I-Vaccine104517535
,    O
into    O
its    O
genome    O
that    O
allows    O
the    O
transgenic    O
plant    O
to    O
survive    O
being    O
sprayed    O
by    O
this    O
non    O
-    O
selective    O
herbicide    O
,    O
glyphosate    O
.    O

Gene    O
transfer    O
into    O
the    O
genome    O
of    O
the    O
desired    O
organism    O
,    O
as    O
for    O
fish    O
in    O
this    O
case    O
,    O
requires    O
a    O
vector    O
like    O
a    O
lentivirus    O
or    O
mechanical    O
/    O
physical    O
insertion    O
of    O
the    O
altered    O
genes    O
into    O
the    O
nucleus    O
of    O
the    O
host    O
by    O
means    O
of    O
a    O
micro    O
syringe    O
or    O
a    O
gene    B-Vaccine104517535
gun    I-Vaccine104517535
.    O

PRSV    O
's    O
coat    O
protein    O
gene    O
was    O
inserted    O
into    O
highly    O
embryogenic    O
plant    O
tissue    O
by    O
using    O
the    O
newly    O
invented    O
gene    B-Vaccine104517535
gun    I-Vaccine104517535
,    O
which    O
led    O
to    O
the    O
development    O
of    O
the    O
transgenic    O
line    O
55    O
-    O
1    O
,    O
which    O
was    O
proven    O
to    O
be    O
effective    O
at    O
controlling    O
Hawaiian    O
strains    O
of    O
PRSV    O
.    O

Scientists    O
there    O
used    O
gold    B-Vaccine104517535
bead    I-Vaccine104517535
gene    O
transfer    O
technology    O
coupled    O
with    O
the    O
Î²-Glucuronidase    O
reporter    O
gene    O
to    O
produce    O
the    O
plant    O
.    O

Tick-borne    B-Vaccine104517535
encephalitis    I-Vaccine104517535
vaccine    I-Vaccine104517535

Information    O
that    O
the    O
health    O
authorities    O
obtained    O
during    O
the    O
vaccine    O
development    O
were    O
subsequently    O
passed    O
on    O
to    O
Chiron    O
(    O
now    O
GlaxoSmithKline    O
)    O
,    O
who    O
developed    O
a    O
similar    O
vaccine    O
,    O
MeNZB    B-Vaccine104517535
,    O
for    O
New    O
Zealand    O
.    O

Helene    O
Mambu    O
joined    O
the    O
Department    O
of    O
Health    O
of    O
Zaire    O
in    O
1981    O
,    O
as    O
the    O
countrywide    O
deputy    O
-    O
director    O
of    O
the    O
joint    O
division    O
for    O
combating    O
child    O
communicable    O
diseases    O
(    O
CCCD    O
)    O
,    O
and    O
the    O
Expanded    B-Vaccine104517535
Program    I-Vaccine104517535
on    I-Vaccine104517535
Immunization    I-Vaccine104517535
(    O
EPI    O
)    O
.    O

The    O
institution    O
organizes    O
and    O
applies    O
the    O
strategy    O
of    O
public    O
health    O
(    O
hygienic    O
-    O
sanitary    O
measures    O
,    O
prophylactic    O
-    O
epidemically    O
measures    O
,    O
social    O
-    O
medical    O
,    O
health    O
education    O
,    O
EPI    B-Vaccine104517535
(    O
expanded    O
program    O
on    O
immunization    O
)    O
,    O
health    O
promotion    O
,    O
water    O
,    O
food    O
and    O
air    O
quality    O
controls    O
,    O
health    O
policy    O
,    O
economy    O
of    O
health    O
,    O
and    O
develops    O
scientific    O
research    O
works    O
in    O
the    O
territory    O
of    O
the    O
Republic    O
of    O
Kosovo    O
.    O

The    O
multi    O
-    O
dose    O
versions    O
of    O
the    O
Influenza    B-Vaccine104517535
vaccine    I-Vaccine104517535
Fluvirin    O
and    O
Fluzone    B-Vaccine104517535
can    O
contain    O
up    O
to    O
25    O
micrograms    O
of    O
mercury    O
per    O
dose    O
from    O
Thiomersal    O
.    O

On    O
January    O
17    O
,    O
2013    O
,    O
the    O
U.S.    O
FDA    O
approved    O
Flublok    B-Vaccine104517535
,    O
a    O
faster    O
-    O
turnaround    O
influenza    O
vaccine    O
which    O
is    O
the    O
first    O
grown    O
in    O
insect    O
cells    O
instead    O
of    O
eggs    O
.    O

Epsteinâ€“Barr    B-Vaccine104517535
virus    I-Vaccine104517535
vaccine    I-Vaccine104517535

Its    O
supply    O
is    O
being    O
replaced    O
by    O
ACAM2000    B-Vaccine104517535
,    O
a    O
more    O
modern    O
product    O
manufactured    O
in    O
laboratories    O
by    O
Acambis    O
,    O
now    O
a    O
division    O
of    O
Sanofi    O
Pasteur    O
.    O

A    O
Trypanosomiasis    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
a    O
vaccine    O
against    O
trypanosomiasis    O
.    O

It    O
is    O
in    O
its    O
premises    O
that    O
the    O
Bacillus    B-Vaccine104517535
Calmette-GuÃ©rin    I-Vaccine104517535
(    O
BCG    O
)    O
vaccine    O
against    O
tuberculosis    O
was    O
invented    O
by    O
Albert    O
Calmette    O
and    O
Camille    O
GuÃ©rin    O
.    O

Bacillus    B-Vaccine104517535
Calmette-GuÃ©rin    I-Vaccine104517535

Until    O
2005    O
,    O
the    O
test    O
was    O
used    O
in    O
the    O
United    O
Kingdom    O
to    O
determine    O
if    O
the    O
BCG    B-Vaccine104517535
vaccine    O
was    O
needed    O
;    O
the    O
Mantoux    O
test    O
is    O
now    O
used    O
instead    O
.    O

Patients    O
who    O
exhibited    O
a    O
negative    O
reaction    O
to    O
the    O
test    O
were    O
considered    O
for    O
BCG    B-Vaccine104517535
vaccination    O
.    O

BCG    B-Vaccine104517535
vaccine    I-Vaccine104517535

There    O
KnÃ¶ll    O
initiated    O
BCG    B-Vaccine104517535
production    O
,    O
which    O
was    O
used    O
for    O
the    O
tuberculosis    O
vaccination    O
regime    O
in    O
the    O
GDR    O
.    O

The    O
test    O
may    O
be    O
falsely    O
positive    O
in    O
those    O
who    O
have    O
been    O
previously    O
vaccinated    O
with    O
BCG    B-Vaccine104517535
or    O
have    O
been    O
infected    O
by    O
other    O
types    O
of    O
mycobacteria    O
.    O

Disseminated    O
BCG    B-Vaccine104517535
infections    O
occur    O
in    O
infants    O
with    O
SCID    O
or    O
with    O
other    O
severe    O
T    O
cell    O
defects    O
.    O

He    O
championed    O
the    O
effective    O
treatment    O
of    O
tuberculosis    O
,    O
including    O
the    O
use    O
of    O
Bacillus    B-Vaccine104517535
Calmette-GuÃ©rin    I-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

It    O
has    O
been    O
proposed    O
that    O
high    O
"    O
MUT    O
"    O
expression    O
(    O
thus    O
high    O
methylmalonyl    O
-    O
CoA    O
mutase    O
levels    O
)    O
leads    O
to    O
lower    O
cholesterol    O
levels    O
which    O
increases    O
resistance    O
to    O
bTB    O
and    O
affords    O
an    O
improved    O
response    O
to    O
the    O
BCG    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

The    O
AUA    O
guidelines    O
also    O
listed    O
several    O
discontinued    O
treatments    O
,    O
including    O
long    O
-    O
term    O
oral    O
antibiotics    O
,    O
intravesical    O
bacillus    B-Vaccine104517535
Calmette    I-Vaccine104517535
Guerin    I-Vaccine104517535
,    O
intravesical    O
resiniferatoxin    O
)    O
,    O
high    O
-    O
pressure    O
and    O
long    O
-    O
duration    O
hydrodistention    O
,    O
and    O
systemic    O
glucocorticoids    O
.    O

BCG    B-Vaccine104517535
vaccine    I-Vaccine104517535
shows    O
some    O
effects    O

BCG    B-Vaccine104517535
vaccine    I-Vaccine104517535

BCG    B-Vaccine104517535
(    O
intradermic    O
)    O

The    O
World    O
Health    O
Organization    O
(    O
WHO    O
)    O
has    O
suggested    O
that    O
priority    O
should    O
be    O
to    O
develop    O
inactivated    B-Vaccine104517535
vaccine    I-Vaccine104517535
and    O
other    O
non    O
-    O
live    O
vaccines    O
,    O
which    O
are    O
safe    O
to    O
use    O
in    O
pregnant    O
women    O
.    O

It    O
is    O
an    O
attenuated    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
unlike    O
most    O
influenza    O
vaccines    O
,    O
which    O
are    O
inactivated    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Studies    O
on    O
live    O
vaccines    O
have    O
very    O
limited    O
data    O
,    O
but    O
these    O
preparations    O
may    O
be    O
more    O
effective    O
than    O
inactivated    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Hookworm    B-Vaccine104517535
vaccine    I-Vaccine104517535
is    O
a    O
vaccine    O
against    O
hookworm    O
.    O

In    O
the    O
case    O
of    O
infectious    O
rhinitis    O
,    O
vaccination    O
against    O
influenza    B-Vaccine104517535
viruses    I-Vaccine104517535
,    O
adenoviruses    B-Vaccine104517535
,    O
measles    O
,    O
rubella    O
,    O
"    O
Streptococcus    O
pneumoniae    O
"    O
,    O
"Haemophilus    B-Vaccine104517535
influenzae"    I-Vaccine104517535
,    O
diphtheria    B-Vaccine104517535
,    O
"Bacillus    B-Vaccine104517535
anthracis"    I-Vaccine104517535
,    O
and    O
"Bordetella    B-Vaccine104517535
pertussis"    I-Vaccine104517535
may    O
help    O
prevent    O
it    O
.    O

Diphtheria    B-Vaccine104517535
vaccine    I-Vaccine104517535

Vaccinia    B-Vaccine104517535
immune    I-Vaccine104517535
globulin    I-Vaccine104517535
(    O
VIG    O
)    O
is    O
made    O
from    O
the    O
pooled    O
blood    O
of    O
individuals    O
who    O
have    O
been    O
inoculated    O
with    O
the    O
smallpox    O
vaccine    O
.    O

rBCG30    B-Vaccine104517535
(    O
recombinant    O
Bacillus    B-Vaccine104517535
Calmette-GuÃ©rin    I-Vaccine104517535
30    O
)    O
is    O
a    O
prospective    O
vaccine    O
against    O
tuberculosis    O
created    O
by    O
a    O
team    O
headed    O
by    O
Marcus    O
A.    O
Horwitz    O
at    O
UCLA    O
.    O

TA-NIC    B-Vaccine104517535
is    O
a    O
proprietary    O
vaccine    O
in    O
development    O
similar    O
to    O
TA-CD    B-Vaccine104517535
but    O
being    O
used    O
to    O
create    O
human    O
anti    O
-    O
nicotine    O
antibodies    O
in    O
a    O
person    O
to    O
destroy    O
nicotine    O
in    O
the    O
human    O
body    O
so    O
that    O
it    O
is    O
no    O
longer    O
effective    O
.    O

Up    O
until    O
the    O
20th    O
century    O
,    O
there    O
were    O
few    O
federal    O
laws    O
regulating    O
the    O
contents    O
and    O
sale    O
of    O
domestically    O
produced    O
food    O
and    O
pharmaceuticals    O
,    O
with    O
one    O
exception    O
being    O
the    O
short    O
-    O
lived    O
Vaccine    B-Vaccine104517535
Act    I-Vaccine104517535
of    I-Vaccine104517535
1813    I-Vaccine104517535
.    O

Circumsporozoite    O
protein    O
(    O
CSP    O
)    O
is    O
a    O
secreted    O
protein    O
of    O
the    O
sporozoite    O
stage    O
of    O
the    O
malaria    O
parasite    O
(    O
"    O
Plasmodium    O
"    O
sp    O
.    O
)    O
and    O
is    O
the    O
antigenic    O
target    O
of    O
RTS,S    B-Vaccine104517535
,    O
a    O
pre    O
-    O
erythrocytic    O
malaria    O
vaccine    O
currently    O
undergoing    O
clinical    O
trials    O
.    O

The    O
PATH    O
Malaria    O
Vaccine    O
Initiative    O
supports    O
several    O
malaria    O
vaccine    O
candidates    O
at    O
various    O
stages    O
of    O
development    O
around    O
the    O
world    O
,    O
including    O
the    O
most    O
advanced    O
candidate    O
,    O
called    O
RTS,S    B-Vaccine104517535
Researchers    O
are    O
studying    O
RTS    O
,    O
S    O
,    O
made    O
by    O
GlaxoSmithKline    O
,    O
in    O
phase    O
3    O
clinical    O
trials    O
among    O
infants    O
and    O
young    O
children    O
in    O
sub    O
-    O
Saharan    O
Africa    O
.    O

This    O
vaccine    O
for    O
cervical    O
cancer    O
is    O
known    O
as    O
"    O
Gardasil    B-Vaccine104517535
"    O
or    O
"    O
Cervarix    B-Vaccine104517535
"    O
.    O

Cervarix    B-Vaccine104517535
is    O
a    O
vaccine    O
against    O
certain    O
types    O
of    O
cancer    O
-    O
causing    O
human    O
papillomavirus    O
(    O
HPV    O
)    O
.    O

Human    B-Vaccine104517535
papillomavirus    I-Vaccine104517535
vaccine    I-Vaccine104517535
(    O
Gardasil    B-Vaccine104517535
and    O
Cervarix    B-Vaccine104517535
)    O
decreases    O
the    O
risk    O
of    O
developing    O
cervical    O
cancer    O
.    O

NmVac4-A/C/Y/W-135    B-Vaccine104517535
vaccine    O

Since    O
the    O
expression    O
of    O
E6    O
is    O
strictly    O
required    O
for    O
maintenance    O
of    O
a    O
malignant    O
phenotype    O
in    O
HPV    O
-    O
induced    O
cancers    O
,    O
it    O
is    O
an    O
appealing    O
target    O
of    O
therapeutic    O
HPV    B-Vaccine104517535
vaccine    I-Vaccine104517535
designed    O
to    O
eradicate    O
established    O
cervical    O
cancer    O
tumors    O
.    O

Since    O
many    O
,    O
if    O
not    O
most    O
,    O
anal    O
cancers    O
derive    O
from    O
HPV    O
infections    O
,    O
and    O
since    O
the    O
HPV    B-Vaccine104517535
vaccine    I-Vaccine104517535
before    O
exposure    O
to    O
HPV    O
prevents    O
infection    O
by    O
some    O
strains    O
of    O
the    O
virus    O
and    O
has    O
been    O
shown    O
to    O
reduce    O
the    O
incidence    O
of    O
potentially    O
precancerous    O
lesions    O
,    O
scientists    O
surmise    O
that    O
HPV    O
vaccination    O
may    O
reduce    O
the    O
incidence    O
of    O
anal    O
cancer    O
.    O

The    O
budget    O
,    O
labelled    O
"    O
the    O
toughest    O
in    O
many    O
years    O
"    O
,    O
included    O
a    O
number    O
of    O
controversial    O
measures    O
such    O
as    O
a    O
proposed    O
income    O
levy    O
which    O
was    O
eventually    O
restructured    O
,    O
and    O
the    O
withdrawal    O
of    O
previously    O
promised    O
HPV    B-Vaccine104517535
vaccine    I-Vaccine104517535
for    O
schoolgirls    O
.    O

Also    O
recently    O
,    O
the    O
HPV    B-Vaccine104517535
vaccine    I-Vaccine104517535
has    O
become    O
controversial    O
due    O
to    O
concerns    O
that    O
it    O
may    O
encourage    O
promiscuity    O
when    O
given    O
to    O
11-    O
and    O
12-year    O
-    O
old    O
girls    O
.    O

HPV    B-Vaccine104517535
vaccine    I-Vaccine104517535

Grimes    O
has    O
been    O
particularly    O
vocal    O
against    O
the    O
anti    O
-    O
vaccine    O
movement    O
,    O
focusing    O
on    O
assertions    O
by    O
anti    O
-    O
HPV    B-Vaccine104517535
vaccine    I-Vaccine104517535
groups    O
whose    O
arguments    O
,    O
Grimes    O
says    O
,    O
consist    O
of    O
"    O
anecdotes    O
,    O
emotive    O
appeals    O
and    O
easily    O
debunked    O
assertions    O
"    O
,    O
opining    O
that    O
"    O
lives    O
of    O
countless    O
young    O
men    O
and    O
women    O
count    O
on    O
us    O
being    O
guided    O
by    O
evidence    O
rather    O
than    O
rhetoric    O
.    O
"    O

For    O
example    O
,    O
the    O
Family    O
Research    O
Council    O
opposes    O
mandatory    O
vaccination    B-Vaccine104517535
against    I-Vaccine104517535
the    I-Vaccine104517535
human    I-Vaccine104517535
papillomavirus    I-Vaccine104517535
,    O
writing    O
,    O
"    O
Our    O
primary    O
concern    O
is    O
with    O
the    O
message    O
that    O
would    O
be    O
delivered    O
to    O
nine-    O
to    O
12-year    O
-    O
olds    O
with    O
the    O
administration    O
of    O
the    O
vaccines    O
.    O

A    O
2011    O
study    O
examining    O
pediatricians    O
'    O
behaviors    O
surrounding    O
the    O
Human    B-Vaccine104517535
Papillomavirus    I-Vaccine104517535
(HPV)    I-Vaccine104517535
vaccine    I-Vaccine104517535
found    O
that    O
TRA    O
predicted    O
the    O
pediatricians    O
would    O
encourage    O
parents    O
to    O
get    O
their    O
daughters    O
vaccinated    O
.    O

In    O
December    O
2013    O
,    O
Couric    O
ran    O
a    O
segment    O
on    O
the    O
HPV    B-Vaccine104517535
vaccine    I-Vaccine104517535
which    O
critics    O
accused    O
of    O
being    O
too    O
sympathetic    O
to    O
the    O
scientifically    O
unsupported    O
claims    O
that    O
this    O
vaccine    O
was    O
dangerous    O
.    O

Georgetown    O
's    O
Vincent    O
Lombardi    O
Cancer    O
Center    O
is    O
one    O
of    O
41    O
research    O
-    O
intensive    O
comprehensive    O
cancer    O
centers    O
in    O
the    O
United    O
States    O
,    O
and    O
developed    O
the    O
breakthrough    O
HPV    B-Vaccine104517535
vaccine    I-Vaccine104517535
for    O
cervical    O
cancer    O
and    O
Conditionally    O
Reprogrammed    O
Cells    O
(    O
CRC    O
)    O
technology    O
.    O

Human    B-Vaccine104517535
papillomavirus    I-Vaccine104517535
vaccine    I-Vaccine104517535
(    O
Gardasil    B-Vaccine104517535
and    O
Cervarix    B-Vaccine104517535
)    O
decreases    O
the    O
risk    O
of    O
developing    O
cervical    O
cancer    O
.    O

Sinovac    O
's    O
commercialized    O
vaccines    O
include    O
Healive    O
(    O
hepatitis    O
A    O
)    O
,    O
Bilive    O
(    O
combined    B-Vaccine104517535
hepatitis    I-Vaccine104517535
A    I-Vaccine104517535
and    I-Vaccine104517535
B    I-Vaccine104517535
)    O
,    O
Anflu    O
(    O
influenza    O
)    O
,    O
Panflu    O
(    O
H5N1    O
)    O
and    O
PANFLU.1    O
(    O
H1N1    O
)    O
.    O

Hepatitis    B-Vaccine104517535
B    I-Vaccine104517535
vaccine    I-Vaccine104517535

Manufacturers    O
recommend    O
that    O
hepatitis    B-Vaccine104517535
B    I-Vaccine104517535
vaccine    I-Vaccine104517535
be    O
stored    O
at    O
2    O
-    O
8    O
Â°C    O
,    O
but    O
the    O
vaccines    O
actually    O
tolerate    O
ambient    O
and    O
even    O
high    O
temperatures    O
for    O
some    O
amount    O
of    O
time    O
.    O

Recombinant    O
proteins    O
,    O
such    O
as    O
insulin    O
,    O
hepatitis    B-Vaccine104517535
B    I-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
interferon    O
,    O
granulocyte    O
colony    O
-    O
stimulating    O
factor    O
,    O
streptokinase    O
and    O
others    O
are    O
also    O
made    O
this    O
way    O
.    O

Hepatitis    B-Vaccine104517535
B    I-Vaccine104517535
vaccine    I-Vaccine104517535
---    O
first    O
dose    O

Hepatitis    B-Vaccine104517535
B    I-Vaccine104517535
vaccine    I-Vaccine104517535

The    O
hepatitis    B-Vaccine104517535
B    I-Vaccine104517535
vaccine    I-Vaccine104517535
prevents    O
infection    O
with    O
hepatitis    O
B    O
virus    O
and    O
thus    O
decreases    O
the    O
risk    O
of    O
liver    O
cancer    O
.    O

Preventive    O
efforts    O
include    O
immunization    B-Vaccine104517535
against    I-Vaccine104517535
hepatitis    I-Vaccine104517535
B    I-Vaccine104517535
and    O
treating    O
those    O
infected    O
with    O
hepatitis    O
B    O
or    O
C.    O
Screening    O
is    O
recommended    O
in    O
those    O
with    O
chronic    O
liver    O
disease    O
.    O

One    O
of    O
the    O
most    O
successful    O
primary    O
liver    O
cancer    O
preventions    O
is    O
vaccination    B-Vaccine104517535
against    I-Vaccine104517535
hepatitis    I-Vaccine104517535
B    I-Vaccine104517535
Vaccination    O
against    O
the    O
hepatitis    O
C    O
virus    O
is    O
currently    O
unavailable    O
.    O

In    O
animal    O
models    O
,    O
MVA    O
vaccines    O
have    O
been    O
found    O
to    O
be    O
immunogenic    O
and    O
protective    O
against    O
various    O
infectious    O
agents    O
including    O
immunodeficiency    O
viruses    O
,    O
influenza    O
,    O
parainfluenza    O
,    O
measles    O
virus    O
,    O
flaviviruses    O
,    O
tuberculosis    B-Vaccine104517535
,    O
Plasmodium    O
parasites    O
and    O
smallpox    O
as    O
well    O
as    O
certain    O
cancers    O
.    O

Microbiologist    O
Maurice    O
Hilleman    O
,    O
who    O
would    O
develop    O
nearly    O
40    O
vaccines    O
,    O
including    O
eight    O
of    O
the    O
14    O
on    O
the    O
worldwide    O
vaccination    B-Vaccine104517535
schedule    I-Vaccine104517535
,    O
began    O
the    O
development    O
of    O
the    O
Mumpsvax    B-Vaccine104517535
vaccine    O
against    O
the    O
mumps    O
virus    O
,    O
by    O
harvesting    O
the    O
live    O
virus    O
from    O
his    O
five    O
-    O
year    O
-    O
old    O
daughter    O
.    O

In    O
2014    O
,    O
the    O
Egyptian    O
Ministry    O
of    O
Health    O
introduced    O
the    O
Haemophilus    B-Vaccine104517535
influenzae    I-Vaccine104517535
type    I-Vaccine104517535
B    I-Vaccine104517535
(HiB)    I-Vaccine104517535
vaccine    I-Vaccine104517535
in    O
the    O
National    O
Immunisation    O
Program    O
,    O
an    O
important    O
milestone    O
in    O
the    O
advocacy    O
activities    O
of    O
Healthy    O
Egyptians    O
and    O
the    O
fight    O
against    O
preventable    O
diseases    O
.    O

Research    O
by    O
Richard    O
Moxon    O
into    O
the    O
public    O
health    O
impact    O
of    O
"    O
Haemophilus    O
influenzae    O
"    O
type    O
b    O
(    O
Hib    O
)    O
invasive    O
disease    O
in    O
the    O
UK    O
,    O
and    O
efficacy    O
studies    O
of    O
the    O
Hib    B-Vaccine104517535
conjugate    I-Vaccine104517535
vaccine    I-Vaccine104517535
in    O
UK    O
children    O
,    O
led    O
to    O
the    O
founding    O
of    O
OVG    O
in    O
1994    O
.    O

Haemophilus    B-Vaccine104517535
influenzae    I-Vaccine104517535
type    I-Vaccine104517535
b    I-Vaccine104517535
vaccine    I-Vaccine104517535

He    O
is    O
best    O
known    O
for    O
publishing    O
research    O
concluding    O
that    O
vaccines    O
,    O
in    O
particular    O
the    O
Hib    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
cause    O
insulin    O
-    O
dependent    O
diabetes    O
mellitus    O
,    O
a    O
hypothesis    O
he    O
proposed    O
based    O
on    O
experiments    O
he    O
conducted    O
on    O
mice    O
in    O
1996    O
.    O

Hib    B-Vaccine104517535
vaccine    I-Vaccine104517535
to    O
infants    O

"    O
Heterosubtypic    B-Vaccine104517535
immunity    I-Vaccine104517535
(    O
HSI    O
)    O
is    O
defined    O
as    O
cross    O
-    O
protection    O
to    O
infection    O
with    O
an    O
influenza    O
A    O
virus    O
serotype    O
other    O
than    O
the    O
one    O
used    O
for    O
primary    O
infection    O
.    O
"    O

In    O
addition    O
to    O
development    O
of    O
Morpholinos    O
as    O
therapeutics    O
,    O
AVI    O
has    O
conducted    O
six    O
human    O
trials    O
for    O
colorectal    O
and    O
pancreatic    O
cancers    O
using    O
their    O
cancer    O
vaccine    O
AVICINE    B-Vaccine104517535
.    O

Dryvax    B-Vaccine104517535
is    O
a    O
freeze    O
-    O
dried    O
calf    B-Vaccine104517535
lymph    I-Vaccine104517535
smallpox    O
vaccine    O
.    O

1937    O
First    O
vaccine    B-Vaccine104517535
for    O
typhus    O

a    O
nasal    O
spray    O
of    O
live    B-Vaccine104517535
attenuated    I-Vaccine104517535
influenza    I-Vaccine104517535
vaccine    I-Vaccine104517535
(    O
LAIV    O
,    O
Q    O
/    O
LAIV    O
)    O
,    O
which    O
contains    O
the    O
attenuated    O
or    O
weakened    O
form    O
of    O
the    O
virus    O
.    O

In    O
the    O
USA    O
:    O
The    O
CDC    O
has    O
indicated    O
that    O
live    B-Vaccine104517535
attenuated    I-Vaccine104517535
influenza    I-Vaccine104517535
vaccine    I-Vaccine104517535
(    O
LAIV    O
)    O
,    O
also    O
called    O
the    O
nasal    O
spray    O
vaccine    O
,    O
is    O
not    O
recommended    O
for    O
the    O
2016â€“2017    O
flu    O
season    O
,    O
in    O
the    O
United    O
States    O
.    O

United    O
States    O
46    O
states    O
and    O
Washington    O
,    O
D.C.    O
begin    O
ordering    O
what    O
becomes    O
by    O
the    O
next    O
day    O
a    O
cumulative    O
total    O
of    O
1,378,200    O
doses    O
of    O
the    O
nasal    O
-    O
spray    O
Live    O
Attenuated    O
Influenza    O
Vaccine    O
(    O
LAIV    B-Vaccine104517535
)    O
for    O
H1N1    O
.    O

Caries    B-Vaccine104517535
vaccine    I-Vaccine104517535
â€¢    O

The    O
European    O
Union    O
has    O
also    O
approved    O
Optaflu    B-Vaccine104517535
,    O
a    O
vaccine    O
produced    O
by    O
Novartis    O
using    O
vats    O
of    O
animal    O
cells    O
.    O

---    O
immunization    B-Vaccine104517535
schedule    I-Vaccine104517535

In    O
the    O
US    O
during    O
the    O
year    O
2001    O
,    O
routine    O
childhood    B-Vaccine104517535
immunizations    I-Vaccine104517535
against    O
seven    O
diseases    O
were    O
estimated    O
to    O
save    O
over    O
$    O
40    O
billion    O
per    O
birth    O
-    O
year    O
cohort    O
in    O
overall    O
social    O
costs    O
,    O
including    O
$    O
10    O
billion    O
in    O
direct    O
health    O
costs    O
,    O
and    O
the    O
societal    O
benefit    O
-    O
cost    O
ratio    O
for    O
these    O
vaccinations    O
was    O
estimated    O
to    O
be    O
16.5    O
.    O

A    O
list    O
of    O
required    O
vaccines    O
in    O
the    O
US    O
can    O
be    O
found    O
on    O
the    O
vaccine    B-Vaccine104517535
schedule    I-Vaccine104517535
page    O
.    O

Microbiologist    O
Maurice    O
Hilleman    O
,    O
who    O
would    O
develop    O
nearly    O
40    O
vaccines    O
,    O
including    O
eight    O
of    O
the    O
14    O
on    O
the    O
worldwide    O
vaccination    B-Vaccine104517535
schedule    I-Vaccine104517535
,    O
began    O
the    O
development    O
of    O
the    O
Mumpsvax    B-Vaccine104517535
vaccine    O
against    O
the    O
mumps    O
virus    O
,    O
by    O
harvesting    O
the    O
live    O
virus    O
from    O
his    O
five    O
-    O
year    O
-    O
old    O
daughter    O
.    O

This    O
can    O
be    O
the    O
reason    O
for    O
distinct    O
time    O
frames    O
found    O
in    O
vaccination    B-Vaccine104517535
schedule    I-Vaccine104517535
.    O

In    O
the    O
case    O
of    O
infectious    O
rhinitis    O
,    O
vaccination    O
against    O
influenza    B-Vaccine104517535
viruses    I-Vaccine104517535
,    O
adenoviruses    B-Vaccine104517535
,    O
measles    O
,    O
rubella    O
,    O
"    O
Streptococcus    O
pneumoniae    O
"    O
,    O
"Haemophilus    B-Vaccine104517535
influenzae"    I-Vaccine104517535
,    O
diphtheria    B-Vaccine104517535
,    O
"Bacillus    B-Vaccine104517535
anthracis"    I-Vaccine104517535
,    O
and    O
"Bordetella    B-Vaccine104517535
pertussis"    I-Vaccine104517535
may    O
help    O
prevent    O
it    O
.    O

When    O
the    O
U.S.    O
military    O
began    O
requiring    O
its    O
troops    O
to    O
receive    O
the    O
anthrax    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
multiple    O
US    O
military    O
troops    O
refused    O
to    O
do    O
so    O
,    O
which    O
led    O
to    O
threats    O
of    O
military    O
courts    O
martial    O
.    O

The    O
Anthrax    O
Vaccine    O
Immunization    O
Program    O
(    O
AVIP    O
)    O
,    O
is    O
the    O
name    O
of    O
the    O
policy    O
set    O
forth    O
by    O
the    O
U.S.    O
federal    O
government    O
to    O
immunize    O
its    O
military    O
and    O
certain    O
civilian    O
personnel    O
with    O
the    O
"    O
BioThrax    B-Vaccine104517535
"    O
anthrax    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Anthrax    B-Vaccine104517535
vaccine    I-Vaccine104517535

Trimidox    B-Vaccine104517535
-    O
antibacterial    O
containing    O
trimethoprim    O
and    O
sulfadoxine    O

Mumps    B-Vaccine104517535
vaccines    I-Vaccine104517535
are    O
vaccines    O
which    O
prevent    O
mumps    O
.    O

1967    O
First    O
vaccine    B-Vaccine104517535
for    O
mumps    O

Mumps    B-Vaccine104517535
vaccine    I-Vaccine104517535

The    O
latter    O
causes    O
tetanus    O
and    O
is    O
vaccinated    O
against    O
by    O
the    O
DTaP    B-Vaccine104517535
vaccine    O
.    O

DPT    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
a    O
vaccine    O
against    O
diphtheria    O
,    O
pertussis    O
and    O
tetanus    O

Later    O
20th    O
-    O
century    O
events    O
included    O
the    O
1982    O
broadcast    O
of    O
"    O
DPT    O
:    O
Vaccine    O
Roulette    O
"    O
,    O
which    O
sparked    O
debate    O
over    O
the    O
DPT    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
and    O
the    O
1998    O
publication    O
of    O
a    O
fraudulent    O
academic    O
article    O
by    O
Andrew    O
Wakefield    O
which    O
sparked    O
the    O
MMR    O
vaccine    O
controversy    O
.    O

Of    O
the    O
1,008    O
children    O
in    O
the    O
study    O
,    O
one    O
quarter    O
of    O
those    O
diagnosed    O
with    O
autism    O
were    O
born    O
between    O
1994    O
and    O
1999    O
,    O
when    O
the    O
routine    O
vaccine    O
schedule    O
could    O
contain    O
more    O
than    O
3,000    O
antigens    O
(    O
in    O
a    O
single    O
shot    O
of    O
DTP    B-Vaccine104517535
vaccine    I-Vaccine104517535
)    O
.    O

DTaP    B-Vaccine104517535
-    O
IPV    O
---    O
third    O
dose    O

DTaP    B-Vaccine104517535
-    O
IPV    O
---    O
booster    O
dose    O

Pertussis    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
such    O
as    O
in    O
DPT    B-Vaccine104517535
vaccine    I-Vaccine104517535

Tetanus    B-Vaccine104517535
vaccine    I-Vaccine104517535
(    O
such    O
as    O
in    O
the    O
DPT    B-Vaccine104517535
vaccine    I-Vaccine104517535
)    O

DPT    B-Vaccine104517535
vaccine    I-Vaccine104517535

Immunization    O
(    O
which    O
is    O
impermanent    O
and    O
must    O
be    O
repeated    O
periodically    O
)    O
instead    O
utilizes    O
the    O
less    O
deadly    O
toxoid    O
derived    O
from    O
the    O
toxin    O
,    O
as    O
in    O
the    O
tetanus    B-Vaccine104517535
vaccine    I-Vaccine104517535
and    O
some    O
combination    O
vaccines    O
(    O
such    O
as    O
DTP    B-Vaccine104517535
)    O
.    O

Triple    B-Vaccine104517535
vaccine    I-Vaccine104517535
:    O
Diphtheria    O
-    O
Tetanus    O
-    O
Pertussis    O

1954    O
First    O
vaccine    B-Vaccine104517535
for    O
Japanese    O
encephalitis    O

Japanese    B-Vaccine104517535
encephalitis    I-Vaccine104517535
vaccine    I-Vaccine104517535

The    O
first    O
DIVA    O
vaccines    O
(    O
formerly    O
termed    O
marker    B-Vaccine104517535
vaccine    I-Vaccine104517535
and    O
since    O
1999    O
coined    O
as    O
DIVA    O
vaccines    O
)    O
and    O
companion    O
diagnostic    O
tests    O
have    O
been    O
developed    O
by    O

The    O
vaccine    O
contains    O
the    O
MF59C.1    B-Vaccine104517535
adjuvant    I-Vaccine104517535
which    O
is    O
an    O
oil    O
-    O
in    O
-    O
water    O
emulsion    O
of    O
squalene    O
oil    O
.    O

Currently    O
,    O
his    O
main    O
research    O
focus    O
is    O
on    O
the    O
identification    O
of    O
new    O
targets    O
for    O
therapeutic    O
intervention    O
in    O
malaria    O
and    O
the    O
development    O
of    O
a    O
malaria    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

2015    O
First    O
vaccine    B-Vaccine104517535
for    O
malaria    O

This    O
parasitic    O
antigen    O
diversity    O
is    O
particularly    O
troublesome    O
for    O
the    O
development    O
of    O
the    O
malaria    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

In    O
its    O
latest    O
trial    O
,    O
a    O
new    O
malaria    B-Vaccine104517535
vaccine    I-Vaccine104517535
has    O
been    O
shown    O
to    O
be    O
100    O
percent    O
effective    O
.    O

This    O
work    O
became    O
the    O
basis    O
for    O
subsequent    O
ongoing    O
research    O
into    O
a    O
malaria    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

In    O
a    O
series    O
of    O
reports    O
between    O
2004    O
and    O
2010    O
,    O
Deer    O
investigated    O
concerns    O
over    O
the    O
MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
that    O
arose    O
with    O
the    O
publication    O
in    O
1998    O
of    O
a    O
research    O
paper    O
in    O
the    O
medical    O
journal    O
"    O
The    O
Lancet    O
"    O
written    O
by    O
Andrew    O
Wakefield    O
,    O
and    O
his    O
colleagues    O
.    O

Professor    O
Jones    O
gave    O
reporting    O
of    O
the    O
safety    O
of    O
the    O
MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
and    O
more    O
recent    O
coverage    O
of    O
claims    O
about    O
the    O
safety    O
of    O
GM    O
crops    O
and    O
the    O
existence    O
of    O
man    O
made    O
climate    O
change    O
as    O
examples    O
of    O
his    O
point    O
.    O

These    O
have    O
allowed    O
the    O
further    O
evaluation    O
and    O
ennumeration    O
of    O
its    O
efficacy    O
(    O
~75â€“85%    O
after    O
two    O
doses    O
of    O
MMR    B-Vaccine104517535
)    O
.    O

Multiple    O
studies    O
have    O
shown    O
no    O
connection    O
between    O
the    O
MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
and    O
autism    O
.    O

In    O
the    O
UK    O
,    O
the    O
MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
was    O
the    O
subject    O
of    O
controversy    O
after    O
the    O
publication    O
in    O
"    O
The    O
Lancet    O
"    O
of    O
a    O
1998    O
paper    O
by    O
Andrew    O
Wakefield    O
and    O
others    O
reporting    O
case    O
histories    O
of    O
12    O
children    O
mostly    O
with    O
autism    O
spectrum    O
disorders    O
with    O
onset    O
soon    O
after    O
administration    O
of    O
the    O
vaccine    O
.    O

...    O
We    O
do    O
n't    O
know    O
what    O
,    O
if    O
any    O
,    O
kind    O
of    O
link    O
there    O
is    O
between    O
vaccines    O
and    O
autism    O
â€”    O
but    O
we    O
should    O
find    O
out    O
.    O
"    O
This    O
statement    O
was    O
made    O
two    O
years    O
before    O
2010    O
,    O
when    O
a    O
study    O
published    O
in    O
1998    O
alleging    O
that    O
the    O
MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
caused    O
autism    O
was    O
retracted    O
after    O
it    O
was    O
found    O
to    O
have    O
been    O
fraudulent    O
.    O

His    O
study    O
,    O
which    O
included    O
a    O
total    O
of    O
12    O
children    O
,    O
implied    O
that    O
the    O
MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
causes    O
autism    O
and    O
autistic    O
enterocolitis    O
.    O

MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
,    O
for    O
measles    O
,    O
mumps    O
and    O
rubella    O

When    O
Wakefield    O
and    O
his    O
colleagues    O
first    O
reported    O
in    O
1998    O
a    O
possible    O
association    O
between    O
autistic    O
regression    O
,    O
inflammatory    O
bowel    O
disease    O
(    O
IBD    O
)    O
,    O
and    O
MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
in    O
the    O
"    O
Lancet    O
"    O
,    O
they    O
evaluated    O
a    O
dozen    O
children    O
with    O
pervasive    O
developmental    O
disorders    O
,    O
apparent    O
developmental    O
regression    O
,    O
and    O
intestinal    O
symptoms    O
,    O
referred    O
to    O
the    O
Royal    O
Free    O
Hospital    O
.    O

The    O
MMR    O
vaccine    O
controversy    O
started    O
with    O
the    O
1998    O
publication    O
of    O
a    O
fraudulent    O
research    O
paper    O
in    O
"    O
The    O
Lancet    O
"    O
linking    O
the    O
combined    B-Vaccine104517535
measles,    I-Vaccine104517535
mumps,    I-Vaccine104517535
and    I-Vaccine104517535
rubella    I-Vaccine104517535
(MMR)    I-Vaccine104517535
vaccine    I-Vaccine104517535
to    O
colitis    O
and    O
autism    O
spectrum    O
disorders    O
.    O

The    O
first    O
MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
to    O
be    O
administered    O
in    O
the    O
UK    O
was    O
given    O
by    O
Dr    O
Benjamin    O
Paterson    O
at    O
Warrington    O
General    O
Hospital    O
in    O
1971    O
.    O

Trafford    O
ignores    O
her    O
wishes    O
and    O
secretly    O
vaccinates    O
Caitlin    O
against    O
measles,    B-Vaccine104517535
mumps    I-Vaccine104517535
and    O
tetanus    O
.    O

In    O
1998    O
,    O
Andrew    O
Wakefield    O
and    O
his    O
colleagues    O
published    O
a    O
fraudulent    O
research    O
paper    O
and    O
he    O
claimed    O
to    O
link    O
the    O
MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
with    O
autism    O
.    O

MRC-5    O
cells    O
are    O
used    O
to    O
produce    O
several    O
vaccines    O
including    O
MMR    B-Vaccine104517535
,    O
Varicella    B-Vaccine104517535
and    O
Polio    B-Vaccine104517535
.    O

Finally    O
,    O
concerns    O
exist    O
about    O
the    O
quality    O
of    O
user    O
-    O
generated    O
content    O
leading    O
to    O
misinformation    O
,    O
such    O
as    O
perpetuating    O
the    O
discredited    O
claim    O
that    O
the    O
MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
may    O
cause    O
autism    O
.    O

In    O
2002    O
,    O
Shattock    O
conducted    O
a    O
survey    O
and    O
claimed    O
that    O
this    O
survey    O
had    O
identified    O
a    O
unique    O
subset    O
of    O
autistic    O
children    O
who    O
may    O
be    O
uniquely    O
susceptible    O
to    O
the    O
MMR    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

Oculo-respiratory    B-Vaccine104517535
syndrome    I-Vaccine104517535
is    O
a    O
usually    O
transient    O
condition    O
characterized    O
by    O
bilateral    O
conjunctivitis    O
,    O
facial    O
edema    O
,    O
and    O
upper    O
respiratory    O
symptoms    O
following    O
influenza    O
immunization    O
.    O

The    O
Anthrax    O
Vaccine    O
Immunization    O
Program    O
(    O
AVIP    O
)    O
,    O
is    O
the    O
name    O
of    O
the    O
policy    O
set    O
forth    O
by    O
the    O
U.S.    O
federal    O
government    O
to    O
immunize    O
its    O
military    O
and    O
certain    O
civilian    O
personnel    O
with    O
the    O
"    O
BioThrax    B-Vaccine104517535
"    O
anthrax    B-Vaccine104517535
vaccine    I-Vaccine104517535
.    O

In    O
1998    O
,    O
the    O
Clinton    O
administration    O
required    O
the    O
inoculation    O
of    O
all    O
military    O
members    O
with    O
the    O
anthrax    O
vaccine    O
known    O
as    O
Anthrax    B-Vaccine104517535
Vaccine    I-Vaccine104517535
Adsorbed    I-Vaccine104517535
(    O
AVA    O
)    O
and    O
by    O
the    O
trade    O
name    O
"    O
BioThrax    O
"    O
.    O

There    O
is    O
a    O
live    B-Vaccine104517535
viral    I-Vaccine104517535
vaccine    I-Vaccine104517535
available    O
which    O
may    O
have    O
beneficial    O
properties    O
against    O
human    O
cancer    O
when    O
used    O
as    O
a    O
mammalian    O
expression    O
vector    O
.    O

This    O
vaccine    O
was    O
a    O
recombinant    O
DNA    O
vaccine    O
based    O
on    O
adenovirus    O
5    O
as    O
a    O
live    B-Vaccine104517535
vector    I-Vaccine104517535
vaccine    I-Vaccine104517535
which    O
was    O
carrying    O
artificial    O
genetic    O
material    O
matching    O
HIV    O
antigens    O
of    O
the    O
three    O
major    O
HIV    O
subtypes    O
.    O


